<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS199802</article-id><article-id pub-id-type="doi">10.1101/2024.10.28.620471</article-id><article-id pub-id-type="archive">PPR933442</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Cancer-cell-derived cGAMP limits the activity of tumorassociated CD8<sup>+</sup> T cells</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Herbst</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Köksal</surname><given-names>Hakan</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Brunn</surname><given-names>Silvan</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zanetti</surname><given-names>Dominik</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Domocos</surname><given-names>Ioana</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>De Stefani</surname><given-names>Viola</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pereira</surname><given-names>Paulo</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nater</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cecconi</surname><given-names>Virginia</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>van den Broek</surname><given-names>Maries</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="CR1">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>Institute of Experimental Immunology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02crff812</institution-id><institution>University of Zurich</institution></institution-wrap>, <country country="CH">Switzerland</country></aff><author-notes><corresp id="CR1"><label>2</label>Corresponding author. Winterthurerstrasse 190, 8057 Zurich, Switzerland. <email>vandenbroek@immunology.uzh.ch</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>02</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="preprint"><day>31</day><month>10</month><year>2024</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1">Using a mouse tumor model with inducible cancer-cell-intrinsic cGAS expression, we show that cancer-cell-derived cGAMP is essential and sufficient to trigger a sustained type I interferon response within the tumor microenvironment. This led to improved CD8<sup>+</sup> T cell-dependent tumor restriction. However, cGAMP limits the proliferation, survival, and function of STING-expressing but not of STING-deficient CD8<sup>+</sup> T cells. <italic>In vivo</italic>, STING deficiency in CD8<sup>+</sup> T cells enhanced tumor restriction. Consequently, cancer-cell-derived cGAMP both drives and limits the anti-tumor potential of CD8<sup>+</sup> T cells. Mechanistically, T cell-intrinsic STING is associated with pro-apoptotic and antiproliferative gene signatures. Our findings suggest that STING signaling acts as a checkpoint in CD8<sup>+</sup> T cells that balances tumor immunity. <fig id="F7" position="anchor"><graphic xlink:href="EMS199802-f007"/></fig>
</p></abstract><kwd-group><kwd>Immunity</kwd><kwd>Cancer</kwd><kwd>Tumor microenvironment</kwd><kwd>cGAS</kwd><kwd>cGAMP</kwd><kwd>STING</kwd><kwd>CD8<sup>+</sup> T cells</kwd></kwd-group></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P2">The presence of type I interferons (IFN-I) in the tumor microenvironment (TME) is essential for the generation of protective anti-tumor immune responses <sup><xref ref-type="bibr" rid="R1">1</xref>–<xref ref-type="bibr" rid="R4">4</xref></sup>, largely through promoting antigen presentation and activating effector CD8<sup>+</sup> T cells. IFN-I production occurs downstream of the cGAS-STING signaling pathway. This pathway is initiated when cytosolic double-stranded DNA (dsDNA) binds to cyclic GMP-AMP synthase (cGAS) <sup><xref ref-type="bibr" rid="R5">5</xref></sup>, which catalyzes the formation of the second messenger cyclic GMP-AMP (cGAMP) <sup><xref ref-type="bibr" rid="R6">6</xref>–<xref ref-type="bibr" rid="R10">10</xref></sup>. Subsequent binding of cGAMP to stimulator of interferon genes (STING) <sup><xref ref-type="bibr" rid="R11">11</xref></sup> results in the recruitment of TANK-binding kinase 1 (TBK1) <sup><xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R13">13</xref></sup> and phosphorylation of interferon regulatory factor 3 (IRF3) <sup><xref ref-type="bibr" rid="R14">14</xref>,<xref ref-type="bibr" rid="R15">15</xref></sup>. Phosphorylated IRF3 then promotes transcription of IFN-I-encoding genes <sup><xref ref-type="bibr" rid="R16">16</xref></sup>.</p><p id="P3">Whereas eukaryotic cells hardly contain cytosolic dsDNA in steady state, they contain substantial amounts under pathological conditions including viral infection, DNA damage, genomic instability, and cancer <sup><xref ref-type="bibr" rid="R17">17</xref></sup>, which usually results in IFN-I production. However, cancer cells often lose their capacity to spontaneously produce IFN-I, suggesting that defects in the cGAS-STING pathway serve to escape immune surveillance <sup><xref ref-type="bibr" rid="R18">18</xref>,<xref ref-type="bibr" rid="R19">19</xref></sup>. We and others showed that cGAMP can be transferred to other cells in the TME <sup><xref ref-type="bibr" rid="R19">19</xref>–<xref ref-type="bibr" rid="R23">23</xref></sup> to activate STING with subsequent IFN-I production <sup><xref ref-type="bibr" rid="R19">19</xref>,<xref ref-type="bibr" rid="R24">24</xref></sup>. Despite the positive association between STING activation, IFN-I production and immune-mediated tumor control, STING signaling appears to play an ambiguous role in the TME. For example, intratumoral administration of a high amount of STING agonist resulted in the death of CD8<sup>+</sup> T cells, and consequently compromised immune-mediated tumor control <sup><xref ref-type="bibr" rid="R25">25</xref></sup>. STING signaling-induced T cell death was shown to rely on IRF3-driven upregulation of pro-apoptotic BH3 <sup><xref ref-type="bibr" rid="R26">26</xref></sup> and disrupted calcium homeostasis <sup><xref ref-type="bibr" rid="R27">27</xref></sup>. Further, STING signaling in T cells reduces their proliferation <sup><xref ref-type="bibr" rid="R28">28</xref>–<xref ref-type="bibr" rid="R30">30</xref></sup>, presumably in an NF-κB-dependent fashion <sup><xref ref-type="bibr" rid="R29">29</xref></sup>. The functions of STING in murine T cells seem largely independent of IFN-I production <sup><xref ref-type="bibr" rid="R31">31</xref></sup>. A study with primary human T cells showed that T cell-intrinsic STING activation enabled IFN-I production, but similarly impaired their function <sup><xref ref-type="bibr" rid="R32">32</xref></sup>. Conversely, STING was required in adoptively transferred CD8<sup>+</sup> T cells to maintain tumor-restricting efficacy <sup><xref ref-type="bibr" rid="R33">33</xref></sup>. These contrasting findings suggest that deeper investigation into STING signaling in the TME and its effects on T cell responses is needed.</p><p id="P4">Most studies on STING signaling in T cells so far focused on CD4<sup>+</sup> T cells and utilized artificial STING agonists <sup><xref ref-type="bibr" rid="R26">26</xref>,<xref ref-type="bibr" rid="R28">28</xref>,<xref ref-type="bibr" rid="R29">29</xref></sup>, whereas only limited attention was given to CD8<sup>+</sup> T cells in the TME. Whether tumor-derived cGAMP is sufficient to influence T cell-intrinsic STING signaling and how this affects the function of tumor-associated CD8<sup>+</sup> T cells is unclear. The concept of enhancing adaptive immune responses by artificial STING agonists received considerable attention in the context of cancer <sup><xref ref-type="bibr" rid="R34">34</xref></sup>. However, the detailed consequences of the transfer of cGAMP within the TME remain poorly understood.</p><p id="P5">Here, we show that cancer-cell-derived cGAMP results in sustained production of IFN-I and improved tumor control. At the same time, however, the activity of STING-expressing tumor-specific CD8<sup>+</sup> T cells is curbed. Mechanistically, T cell-intrinsic STING is associated with pro-apoptotic and antiproliferative gene signatures, such that STING-deficient CD8<sup>+</sup> T cells outcompete STING-expressing CD8<sup>+</sup> T cells <italic>in vivo</italic>. Our findings suggest that STING signaling acts as a checkpoint in CD8<sup>+</sup> T cells that regulates tumor immunity.</p></sec><sec id="S2" sec-type="results"><title>Results</title><sec id="S3"><title>Cancer-cell-intrinsic cGAS expression restricts tumor progression</title><p id="P6">To study the immunological consequences of cancer-cell-derived cGAMP in the TME, we generated murine Lewis lung carcinoma (LLC) cells that express doxycycline (DOX)-inducible cGAS called LLC<sup>cGAStetON</sup> (<xref ref-type="supplementary-material" rid="SD1">Figure S1A</xref>). Parental LLC cells do not express cGAS and hence, don’t produce cGAMP <sup><xref ref-type="bibr" rid="R19">19</xref></sup>. The addition of DOX to cultured LLC<sup>cGAStetON</sup> cells increased cGAS (<italic>Mb21d1</italic>)-transcripts (<xref ref-type="supplementary-material" rid="SD1">Figure S1B</xref>) and cGAS protein (<xref ref-type="supplementary-material" rid="SD1">Figure S1C</xref>). DOX administration to C57BL/6 mice with subcutaneous LLC<sup>cGAStetON</sup> tumors induced the expression of cGAS (<xref ref-type="fig" rid="F1">Figures 1A and 1B</xref>), thus validating the experimental system. Further, we detected an increased concentration of the second messenger cGAMP in lysates of LLC<sup>cGAStetON</sup> cells <italic>in vitro</italic> (<xref ref-type="supplementary-material" rid="SD1">Figure S1D</xref>) and in tumors after induced cGAS expression (<xref ref-type="fig" rid="F1">Figure 1C</xref>). This indicates that sufficient dsDNA is present in LLC<sup>cGAStetON</sup> cells to support cGAS-dependent cGAMP production. Cancer cells can export cGAMP via different mechanisms <sup><xref ref-type="bibr" rid="R20">20</xref>,<xref ref-type="bibr" rid="R21">21</xref>,<xref ref-type="bibr" rid="R35">35</xref></sup>. We confirmed the export of cGAMP by LLC<sup>cGAStetON</sup> cells by measuring cGAMP in the supernatant (<xref ref-type="supplementary-material" rid="SD1">Figure S1E</xref>). While induced cGAS expression did not affect the cell expansion <italic>in vitro</italic> (<xref ref-type="supplementary-material" rid="SD1">Figure S1F</xref>), we observed a significant reduction of subcutaneous (s.c.) tumor growth in immunocompetent C57BL/6 mice (<xref ref-type="fig" rid="F1">Figures 1D and 1E</xref>). DOX administration did not affect the growth of parental LLC tumors (<xref ref-type="fig" rid="F1">Figure 1F</xref>), indicating that reduced tumor progression is due to cancer-cell-intrinsic cGAS, which is in line with previously published work <sup><xref ref-type="bibr" rid="R19">19</xref>,<xref ref-type="bibr" rid="R24">24</xref></sup>. Thus, LLC<sup>cGAStetON</sup> cells can be induced to express cGAS and produce cGAMP, which restricts tumor progression.</p></sec><sec id="S4"><title>Cancer-cell-derived cGAMP promotes a sustained IFN-I response and host STING-dependent tumor control</title><p id="P7">To investigate whether cancer-cell-derived cGAMP activates host STING, we quantified IFN-ß, a member of the type I interferon (IFN-I) family, in LLC<sup>cGAStetON</sup> tumors at different time points after induction of cGAS expression (<xref ref-type="fig" rid="F2">Figure 2A</xref>). Whereas IFN-ß was virtually absent before DOX administration, it was detectable after 16 hours of cGAS induction (<xref ref-type="fig" rid="F2">Figure 2B</xref>). Using Mx1<sup>gfp</sup> IFN-I response reporter mice, we found that both T and myeloid cells responded to IFN-I, with CD11c<sup>+</sup> dendritic cells (DCs) and F4/80<sup>+</sup> macrophages as major responders (<xref ref-type="fig" rid="F2">Figures 2C</xref> and <xref ref-type="supplementary-material" rid="SD1">S2A</xref>). The IFN-I response remained consistent over time, suggesting that cGAMP-releasing tumors maintain an environment of sustained IFN-I response (<xref ref-type="fig" rid="F2">Figure 2D</xref>). cGAMP and IFN-I are potent drivers of DC activation <sup><xref ref-type="bibr" rid="R36">36</xref></sup>. We observed that the production of intratumoral cGAMP and IFN-I induced phenotypic changes in intratumoral DCs. Specifically, we saw an increase in the proportion of activated CD11b<sup>+</sup>Ly6C<sup>+</sup> DCs (<xref ref-type="supplementary-material" rid="SD1">Figures S2B-S2E</xref>), a subset known to differentiate in tumors in response to tumor cell death <sup><xref ref-type="bibr" rid="R37">37</xref></sup>.</p><p id="P8">Since LLC cells express STING <sup><xref ref-type="bibr" rid="R19">19</xref></sup>, we tested whether tumor cells contribute to IFN-I production via intrinsic STING engagement. An ELISA showed detectable IFN-ß in LLC<sup>cGAStetON</sup> cells + DOX <italic>in vitro</italic> (<xref ref-type="supplementary-material" rid="SD1">Figure S2F</xref>). Using CRISPR/Cas9, we generated LLC<sup>cGAStetON-△STING</sup> cells (<xref ref-type="supplementary-material" rid="SD1">Figures S2G and S2H</xref>). While LLC<sup>cGAStetON-△STING</sup> cells produced less IFN-ß <italic>in vitro</italic>, the response to IFN-I <italic>in vivo</italic> was virtually unchanged (<xref ref-type="supplementary-material" rid="SD1">Figures S2I and S2J</xref>), suggesting that cancer-cell intrinsic STING signaling does not contribute to IFN-I in the tumor.</p><p id="P9">We introduced ovalbumin (OVA) in LLC<sup>cGAStetON</sup> cells to allow monitoring of tumorspecific CD8<sup>+</sup> T cells in future experiments and confirmed that induction of cGAS expression in LLC<sup>cGAStetON-OVA</sup> tumors reduced tumor progression (<xref ref-type="supplementary-material" rid="SD1">Figures S2K and S2L</xref>). We verified that the improved control of cGAS-expressing tumors depends on host STING by using STING-deficient hosts (<xref ref-type="supplementary-material" rid="SD1">Figures S2K and S2L</xref>). STING deficiency in cancer cells did not impair tumor control (<xref ref-type="supplementary-material" rid="SD1">Figures S2M and S2N</xref>), providing further evidence for the importance of host STING. Collectively, our data suggest that cancer-cell-derived cGAMP promotes a sustained and host STINGdependent IFN-I response in the TME.</p></sec><sec id="S5"><title>STING-dependent tumor control depends on CD8<sup>+</sup> T cells</title><p id="P10">Because IFN-I enhances antigen (cross-)presentation and the recruitment of CD8<sup>+</sup> T cells to the tumor <sup><xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R38">38</xref></sup>, we analyzed their infiltration in established tumors (<xref ref-type="supplementary-material" rid="SD1">Figure S3A</xref>). Already 5 days after induction of cGAS expression, we observed significantly more CD8<sup>+</sup> T cells per gram of tumor (<xref ref-type="supplementary-material" rid="SD1">Figure S3B</xref>). To assess whether CD8<sup>+</sup> T cells contribute to reduced tumor growth after induction of cancer-cell-intrinsic cGAS, we depleted CD4<sup>+</sup> or CD8<sup>+</sup> T cells starting at the time of DOX administration until the endpoint (<xref ref-type="fig" rid="F3">Figure 3A</xref>). We found that the depletion of CD8<sup>+</sup> but not CD4<sup>+</sup> T cells abrogated the DOX-induced reduction of tumor growth (<xref ref-type="fig" rid="F3">Figures 3B and 3C</xref>). Depletion of CD4<sup>+</sup> or CD8<sup>+</sup> T cells was confirmed by flow cytometry (<xref ref-type="supplementary-material" rid="SD1">Figure S3C</xref>). Next, we investigated the influence of cGAMP and IFN-I on tumor-associated CD8<sup>+</sup> T cells. Using the LLC<sup>cGAStetON-OVA</sup> model we first confirmed that induced cGAS expression reduced tumor progression (<xref ref-type="fig" rid="F3">Figures 3D, 3E</xref> and <xref ref-type="supplementary-material" rid="SD1">S3D</xref>). Clustering analysis (Rphenograph) of flow cytometry data collected 10 days after DOX administration identified 12 CD8<sup>+</sup> T cell clusters. Identified clusters were projected on UMAP (Uniform Manifold Approximation and Projection) plots (<xref ref-type="fig" rid="F3">Figures 3F</xref> and <xref ref-type="supplementary-material" rid="SD1">S3E-S3G</xref>). We found a higher frequency of terminally differentiated T cells (PD-1<sup>high</sup>, TIM3<sup>high</sup>, LAG-3<sup>high</sup>) in −DOX tumors and more active effector T cells (PD-1<sup>+</sup>, TIM3<sup>low</sup>, LAG-3<sup>low</sup>, GzmB<sup>high</sup>) in the +DOX condition (<xref ref-type="fig" rid="F3">Figures 3F and 3G</xref>). The overall proportion of PD-1<sup>+</sup> CD8<sup>+</sup> T cells was higher in the −DOX tumors, while the proportion of proliferating Ki-67<sup>+</sup> CD8<sup>+</sup> T cells was higher in the +DOX condition (<xref ref-type="fig" rid="F3">Figure 3H</xref>). Together, these data suggest that a cGAMP- and IFN-I-rich TME supports the proliferation of infiltrated T cells while restricting their terminal differentiation.</p><p id="P11">Genotoxic treatments increase the concentration of cytoplasmic DNA <sup><xref ref-type="bibr" rid="R39">39</xref>–<xref ref-type="bibr" rid="R43">43</xref></sup>, increase the amount of IFN-I and help to promote CD8<sup>+</sup> T cell-dependent tumor control <sup><xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R19">19</xref>,<xref ref-type="bibr" rid="R44">44</xref></sup>. We therefore proposed that radiotherapy is more efficient in cGAMP-producing LLC<sup>cGAStetON</sup> tumors. To test this hypothesis, we treated mice with LLC<sup>cGAStetON</sup> tumors with a single dose of 20 Gy (<xref ref-type="supplementary-material" rid="SD1">Figure S3H</xref>) as described <sup><xref ref-type="bibr" rid="R44">44</xref>,<xref ref-type="bibr" rid="R45">45</xref></sup>. While the known effects of radiotherapy − reduction of tumor size and an increased number of CD8<sup>+</sup> in the tumor − were detected, these effects were significantly more pronounced in cGAS-expressing LLC<sup>cGAStetON</sup> tumors (<xref ref-type="supplementary-material" rid="SD1">Figures S3I and S3J</xref>). This suggests that cGAS activation and downstream production of cGAMP and IFN-I can be further amplified in our model.</p></sec><sec id="S6"><title>STING signaling in CD8<sup>+</sup> T cells limits their activity <italic>in vitro</italic></title><p id="P12">Production of cGAMP in the TME supports immune-mediated tumor restriction, which requires STING activation in host cells (<xref ref-type="supplementary-material" rid="SD1">Figures S2K and S2L</xref>) <sup><xref ref-type="bibr" rid="R19">19</xref>,<xref ref-type="bibr" rid="R24">24</xref></sup>. cGAMP can be transferred to cells in the TME, and both cell type-specific and non-specific mechanisms have been suggested <sup><xref ref-type="bibr" rid="R19">19</xref>,<xref ref-type="bibr" rid="R20">20</xref>,<xref ref-type="bibr" rid="R22">22</xref>,<xref ref-type="bibr" rid="R23">23</xref>,<xref ref-type="bibr" rid="R35">35</xref>,<xref ref-type="bibr" rid="R46">46</xref>–<xref ref-type="bibr" rid="R49">49</xref></sup>. We hypothesize that cancer-derived cGAMP directly influences CD8<sup>+</sup> T cell behavior in tumors through STING activation. While <italic>in vitro</italic> studies showed that STING activation reduces proliferation and increases cell death of mostly CD4<sup>+</sup> T cells <sup><xref ref-type="bibr" rid="R26">26</xref>,<xref ref-type="bibr" rid="R28">28</xref>,<xref ref-type="bibr" rid="R29">29</xref></sup>, the overall consequences for CD8<sup>+</sup> T cells are less clear.</p><p id="P13">To assess the functional effects of direct STING activation in CD8<sup>+</sup> T cells, we established an <italic>in vitro</italic> assay in which TCR- and STING-signaling are concomitantly activated in OT-I T cells using the natural STING ligand cGAMP. Specifically, we cultured purified STING-proficient (STING<sup>+/+</sup>) or -deficient (STING<sup>−/−</sup>) OT-I CD8<sup>+</sup> T cells with their cognate antigen (SIINFEKL) plus STING<sup>−/−</sup> splenocytes as antigenpresenting cells. To induce STING signaling in OT-I cells, we added cGAMP to the cultures (<xref ref-type="fig" rid="F4">Figure 4A</xref>). Addition of cGAMP significantly reduced multiple features associated with CD8<sup>+</sup> T cell activation, including proliferation (Ki-67) and the expression of granzyme B (GzmB) in STING<sup>+/+</sup> but not in STING<sup>–/–</sup> OT-I CD8<sup>+</sup> T cells (<xref ref-type="fig" rid="F4">Figures 4B-4E</xref>). Further, exogenously added cGAMP resulting in STING signaling in CD8<sup>+</sup> T cells reduced their viability (<xref ref-type="fig" rid="F4">Figure 4F</xref>).</p><p id="P14">Because there is evidence for a connection between STING activation and metabolic fitness of T cells <sup><xref ref-type="bibr" rid="R30">30</xref>,<xref ref-type="bibr" rid="R32">32</xref></sup>, we investigated the effect of exogenous cGAMP and consecutive STING signaling on the overall metabolic activity of cultured OT-I cells using the incorporation of puromycin (PURO) as a proxy 50. Again, exogenously added cGAMP reduced the metabolic activity of STING<sup>+/+</sup> but not of STING<sup>–/–</sup> CD8<sup>+</sup> T cells (<xref ref-type="fig" rid="F4">Figure 4G</xref>).</p><p id="P15">Taken together, our results indicate that STING signaling in CD8<sup>+</sup> T cells diminishes their proliferation, metabolic activity, and survival <italic>in vitro</italic>.</p></sec><sec id="S7"><title>STING signaling in CD8<sup>+</sup> T cells limits their activity <italic>in vivo</italic></title><p id="P16">After showing that STING signaling in CD8<sup>+</sup> T cells reduces their activity <italic>in vitro</italic>, we next performed a series of <italic>in vivo</italic> experiments. First, we investigated the growth of cGAS-expressing tumors using CD4<sup>Cre</sup>STING<sup>flox</sup> mice that lack STING specifically in T cells <sup><xref ref-type="bibr" rid="R33">33</xref>,<xref ref-type="bibr" rid="R51">51</xref></sup>. Conditional STING deficiency was confirmed by flow cytometry (<xref ref-type="supplementary-material" rid="SD1">Figure S4A</xref>). T cell percentages in the thymus and spleen of CD4<sup>Cre+/–</sup>STING<sup>flox</sup> and CD4<sup>Cre-/–</sup>STING<sup>flox</sup> littermates were comparable <sup><xref ref-type="bibr" rid="R33">33</xref></sup> (<xref ref-type="supplementary-material" rid="SD1">Figure S4B</xref>). We induced cGAS expression in LLc<sup>cGAStetON-OVA</sup> tumor-bearing mice (<xref ref-type="fig" rid="F5">Figure 5A</xref>) and found that mice with T cell-specific STING deficiency had significantly smaller tumors than littermate controls (<xref ref-type="fig" rid="F5">Figures 5B and 5C</xref>). We conclude that STING in CD8<sup>+</sup> T cells limits their efficacy in restricting tumors.</p><p id="P17">Next, we directly compared the behavior of tumor-reactive STING<sup>−/−</sup> and STING<sup>+/+</sup>CD8<sup>+</sup> T cells within an identical TME. Based on the STING-dependent reduction of proliferation and survival of CD8<sup>+</sup> T cells described above (<xref ref-type="fig" rid="F4">Figure 4</xref>), we hypothesized that STING<sup>−/−</sup> T cells would outcompete STING<sup>+/+</sup> T cells in a cGAMP-rich TME. To test this, we adoptively co-transferred naïve STING<sup>−/−</sup> (CD45.1/1) and STING<sup>+/+</sup> (CD45.1/2) OT-I CD8<sup>+</sup> T cells into tumor-bearing, TCRß<sup>−/−</sup> (CD45.2/2) hosts that lack endogenous T cells but are otherwise immunocompetent (<xref ref-type="fig" rid="F5">Figure 5D</xref>). We transferred equal numbers of STING<sup>–/–</sup> or STING<sup>+/+</sup> CD8<sup>+</sup> T cells (<xref ref-type="fig" rid="F5">Figures 5E and 5F</xref>). After 10-14 days, we detected significantly more STING<sup>–/–</sup> than STING<sup>+/+</sup> OT-I cells in the tumors, whereas we found similar numbers of STING<sup>–/–</sup> and STING<sup>+/+</sup> OT-I cells in the tumor-draining lymph nodes (tdLN) (<xref ref-type="fig" rid="F5">Figures 5E-5G</xref> and <xref ref-type="supplementary-material" rid="SD1">S4C</xref>). These differences could be explained by a local action of cGAMP, that seemed to be restricted to the tumor site. As a control, we included mice with LLC<sup>OVA</sup> tumors that cannot produce cGAMP and found no differences in T cell frequency in tumor and tdLNs (<xref ref-type="fig" rid="F5">Figures 5H</xref> and <xref ref-type="supplementary-material" rid="SD1">S4D</xref>).</p><p id="P18">Taken together, our results suggest that cancer-cell-derived cGAMP restricts CD8<sup>+</sup> T cells via T cell-intrinsic STING activation in the tumor.</p></sec><sec id="S8"><title>STING activity in CD8<sup>+</sup> T cells promotes their apoptosis and reduces their proliferation in a cGAMP-rich environment</title><p id="P19">To understand the differences between STING-deficient and -proficient intratumoral CD8<sup>+</sup> T cells, we again co-transferred STING<sup>–/–</sup> (CD45.1/1) and STING<sup>+/+</sup> (CD45.1/2) CD8<sup>+</sup> T cells into TCRß<sup>−/−</sup> (CD45.2/2) hosts bearing cGAS-expressing LLC<sup>cGAStetON-OVA</sup> tumors. Six days later, we sorted the transferred CD8<sup>+</sup> T cells from the tumors and performed single-cell RNA sequencing (<xref ref-type="fig" rid="F6">Figures 6A</xref> and <xref ref-type="supplementary-material" rid="SD1">S5A</xref>). Co-transfer and reisolation allowed the comparison of STING-deficient and -proficient CD8<sup>+</sup> T cells from the same TME. As expected, T cells isolated from tumors with a cGAMP-rich TME (+DOX) showed a pronounced interferon response signature compared to − DOX (<xref ref-type="supplementary-material" rid="SD1">Figures S5B and S5C</xref>), thus validating STING activation in the TME. Clustering based on UCell <sup><xref ref-type="bibr" rid="R52">52</xref></sup> scoring indicated fewer exhausted CD8<sup>+</sup> T cells in cGAS-expressing tumors (<xref ref-type="supplementary-material" rid="SD1">Figure S5D</xref>), which goes in line with our previous observations (<xref ref-type="fig" rid="F3">Figures 3F and 3G</xref>). Comparing STING<sup>–/–</sup> and STING<sup>+/+</sup> CD8<sup>+</sup> T cells from the same TME showed overall similar results regarding the frequency of 11 identified cell clusters (<xref ref-type="fig" rid="F6">Figure 6B</xref>). A gene set enrichment analysis (GSEA), however, revealed significant changes in different pathways. Genes associated with apoptosis were downregulated in STING<sup>−/−</sup> T cells, suggesting reduced apoptotic processes in the absence of STING (<xref ref-type="fig" rid="F6">Figure 6C</xref>). This observation was supported by an overall higher differential expression of Caspase 3 (<italic>Casp3</italic>), a key gene in the apoptosis pathway of T cells <sup><xref ref-type="bibr" rid="R53">53</xref></sup>. The association between STING expression and apoptosis aligns with our <italic>in vitro</italic> data where we found reduced cell survival of STING+/+CD8<sup>+</sup> T cells when incubated with cGAMP (<xref ref-type="fig" rid="F4">Figure 4F</xref>) and with previous studies that link STING to apoptosis in T cells <sup><xref ref-type="bibr" rid="R26">26</xref>,<xref ref-type="bibr" rid="R28">28</xref></sup>. Further, the GSEA pointed towards reduced inflammatory responses and signaling via NFkB in STING<sup>–/–</sup> CD8<sup>+</sup> T cells. The fact that NF-kB is a key downstream target of STING may explain this finding. Because NF-κB-dependent antiproliferative effects have been suggested for T cells 29, we compared the proliferating cell fraction (clusters 3 and 7) of STING+/+and STING<sup>–/–</sup> CD8<sup>+</sup> T cells (<xref ref-type="supplementary-material" rid="SD1">Figure S5D</xref>). STING<sup>–/–</sup> T cells expressed significantly higher <italic>Mki67</italic> compared to STING<sup>+/+</sup> T cells, indicating reduced proliferation when STING is present. In addition, <italic>Ifi208</italic> (an IFN-response gene), and <italic>Camta1</italic> and <italic>Grm7</italic> (involved in calcium homeostasis <sup><xref ref-type="bibr" rid="R54">54</xref>,<xref ref-type="bibr" rid="R55">55</xref></sup>) were highly expressed in STING<sup>–/–</sup> T cells (<xref ref-type="supplementary-material" rid="SD1">Figure S5E</xref>). A previous study indicated that STING engagement influences calcium signaling in T cells and leads to apoptosis <sup><xref ref-type="bibr" rid="R27">27</xref></sup>. Of note, we did not detect intrinsic IFN-ß gene expression in reisolated CD8<sup>+</sup> T cells (<xref ref-type="supplementary-material" rid="SD1">Figure S5F</xref>).</p><p id="P20">In conclusion, when CD8<sup>+</sup> T cells are exposed to a cGAMP-rich environment, such as within the TME, STING activation promotes their apoptosis, triggers an inflammatory response, and suppresses their proliferation. Consequently, STING-deficient CD8<sup>+</sup> T cells mediate superior protective anti-tumor immunity. Our findings suggest that STING expression in CD8<sup>+</sup> T cells might act as an additional immune checkpoint in tumors.</p></sec></sec><sec id="S9" sec-type="discussion"><title>Discussion</title><p id="P21">STING-signaling is as a critical pathway for the regulation of immune responses across various cell types, including stromal <sup><xref ref-type="bibr" rid="R12">12</xref></sup>, endothelial <sup><xref ref-type="bibr" rid="R56">56</xref>,<xref ref-type="bibr" rid="R57">57</xref></sup>, epithelial <sup><xref ref-type="bibr" rid="R58">58</xref></sup>, myeloid <sup><xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R36">36</xref>,<xref ref-type="bibr" rid="R59">59</xref></sup>, and lymphoid cells <sup><xref ref-type="bibr" rid="R29">29</xref>,<xref ref-type="bibr" rid="R60">60</xref>,<xref ref-type="bibr" rid="R61">61</xref></sup>. Consistent with previous observations <sup><xref ref-type="bibr" rid="R19">19</xref>,<xref ref-type="bibr" rid="R24">24</xref></sup>, we showed that host STING is essential for tumor restriction in a model with inducible cancer-cell-intrinsic cGAS expression. STING activation was driven by cGAMP-transfer from cancer cells to other cells in the tumor microenvironment and led to CD8<sup>+</sup> T cell-mediated tumor restriction. We demonstrate that cancer-cell-derived cGAMP exerts both beneficial and inhibitory effects on T cell mediated tumor control. There is ample evidence that the activation of STING by cGAMP or artificial STING agonists induces protective anticancer immunity responses, restricts tumor progression, and synergizes with immune checkpoint inhibition <sup><xref ref-type="bibr" rid="R36">36</xref>,<xref ref-type="bibr" rid="R57">57</xref>,<xref ref-type="bibr" rid="R59">59</xref>,<xref ref-type="bibr" rid="R62">62</xref>–<xref ref-type="bibr" rid="R64">64</xref></sup>. However, clinical phase I/II trials combining immunotherapy with STING agonists have shown varying efficacy <sup><xref ref-type="bibr" rid="R34">34</xref></sup>, suggesting that a more precise understanding of the mechanisms underlying STING activation in tumors is needed.</p><p id="P22">Beyond inducing IFN-I, STING activation exerts IFN-I-independent effects, such as promoting different forms of cell death <sup><xref ref-type="bibr" rid="R65">65</xref></sup>. We found that <italic>in vitro</italic> activation of CD8<sup>+</sup> T cells by their cognate antigen was inhibited by addition of exogenous cGAMP. This finding aligns with previous studies showing that concurrent TCR and STING activation impairs T cell proliferation <sup><xref ref-type="bibr" rid="R28">28</xref>,<xref ref-type="bibr" rid="R29">29</xref></sup>. Similarly, metabolic impairment in T cells after TCR and STING activation, presumably due to impaired mTORC1 signaling in an IRF3/IRF7-dependent manner, has been reported <sup><xref ref-type="bibr" rid="R30">30</xref>,<xref ref-type="bibr" rid="R32">32</xref></sup>. We observed STINGdependent inhibition of CD8<sup>+</sup> T cells also in the tumor microenvironment <italic>in vivo</italic>. Our finding that STING-deficient CD8<sup>+</sup> T cells outcompeted STING-proficient ones in the same tumor shows that STING activation inhibits CD8<sup>+</sup> T cells in a cell-intrinsic manner, independent of other cells. Single-cell RNA sequencing data indicated an increased apoptosis-related gene-signature and decreased proliferation-related gene expression in CD8<sup>+</sup> T cells when STING was present. We did not detect <italic>Ifnb</italic> transcripts in CD8<sup>+</sup> T cells, supporting earlier findings that murine T cells can function independently of IFN-I production <sup><xref ref-type="bibr" rid="R31">31</xref></sup> and thus seem to behave differently from human T cells in this aspect <sup><xref ref-type="bibr" rid="R32">32</xref></sup>.</p><p id="P23">While some studies also reported negative effects of STING activation on T cell survival <sup><xref ref-type="bibr" rid="R26">26</xref>,<xref ref-type="bibr" rid="R28">28</xref>,<xref ref-type="bibr" rid="R29">29</xref></sup>, other literature presents conflicting results. For example, Li and colleagues suggested that CD8<sup>+</sup> T cell-intrinsic STING supports tumor-specific functions <sup><xref ref-type="bibr" rid="R33">33</xref></sup>. Along the same line, STING activation in CD4<sup>+</sup> T cells enhanced antitumor responses through supporting differentiation into effector cells <sup><xref ref-type="bibr" rid="R66">66</xref></sup>. A recent study using conditional STING deficiency in T cells suggested slower tumor progression, which was explained by STING activation-dependent expansion of CD4<sup>+</sup> FoxP3<sup>+</sup> regulatory T cells <sup><xref ref-type="bibr" rid="R51">51</xref></sup>. Possible explanations for the above-mentioned discrepancies may be differences in experimental models and readouts. For instance, most studies have used synthetic STING ligands like DMXAA <sup><xref ref-type="bibr" rid="R67">67</xref></sup>, which may act differently compared to cGAMP, as it can exert additional functions beyond STING activation <sup><xref ref-type="bibr" rid="R68">68</xref></sup>. Moreover, locally produced cGAMP may have different effects compared to systemic or intratumorally administered STING agonists.</p><p id="P24">We did not investigate cGAMP transfer mechanisms in the tumor microenvironment or an eventual role of cGAMP-hydrolyzing enzymes like ENPP1 <sup><xref ref-type="bibr" rid="R46">46</xref></sup>. The strong IFN-I production in tumors following induced cGAS expression makes it unlikely that cGAMP-hydrolyzing enzymes play a significant role in our model. LRRC8c <sup><xref ref-type="bibr" rid="R69">69</xref></sup> and SLC19A1 <sup><xref ref-type="bibr" rid="R22">22</xref>,<xref ref-type="bibr" rid="R23">23</xref></sup> have recently been identified as cGAMP importers that can facilitate the uptake of cGAMP. It may be interesting to investigate the contributions of these transporters in modulating immune responses in different cell types within the tumor microenvironment, as well as the effect on immune-mediated tumor restriction.</p><p id="P25">Taken together, we have shown that cancer-cell-derived cGAMP modulates T cell activity, inducing both positive and inhibitory effects. Therapeutic strategies targeting STING should carefully balance innate immune activation with the protection of T cells from STING-mediated inhibition to maximize treatment efficacy. The inhibitory action of STING in CD8<sup>+</sup> T cells could be a contributing factor to CAR-T cell dysfunction in chronic antigen exposure. Thus, it may be worth investigating whether STING-deficient CAR-T cells are more efficacious than STING-expressing counterparts. The fact that T cells retain STING expression throughout differentiation suggests a physiological role for STING as an immune checkpoint, possibly evolved to limit T cell overactivation in chronic inflammatory environments like cancer or persistent viral infection.</p></sec><sec sec-type="methods" id="S10" specific-use="web-only"><title>Star methods</title><sec id="S11"><title>Resource availability</title><sec id="S12"><title>Lead contact</title><p id="P26">Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Maries van den Broek (<email>vandenbroek@immunology.uzh.ch</email>).</p></sec><sec id="S13"><title>Materials availability</title><p id="P27">The materials generated for this study can be provided upon reasonable request.</p></sec></sec><sec id="S14"><title>Experimental model details</title><sec id="S15"><title>Mice</title><p id="P28">C57BL/6NRj mice (8-10 weeks old) were purchased from Janvier Labs. STINGdeficient (STING<sup>−/−</sup>, C57BL/6J-<italic>Stingig1<sup>gt</sup></italic>/J) <sup><xref ref-type="bibr" rid="R70">70</xref></sup>, STING<sup>flox</sup> (B6;SJL-<italic>Sting1<sup>tm1.1Camb</sup></italic>/J) <sup><xref ref-type="bibr" rid="R71">71</xref></sup> and Mx1<sup>gfp</sup> (B6.Cg-<italic>Mx1<sup>tm1.1Agsa</sup></italic>/j) <sup><xref ref-type="bibr" rid="R72">72</xref></sup> mice were purchased from Jackson Laboratory. <italic>Tcrb</italic>- deficient (B6.129P2-<italic>Ţcrb<sup>tm1Mom</sup></italic>/J) <sup><xref ref-type="bibr" rid="R73">73</xref></sup> and CD4<sup>Cre</sup> (STOCK Tg(Cd4- cre)1Cwi/BfluJ) <sup><xref ref-type="bibr" rid="R74">74</xref></sup> mice were originally obtained from the Jackson Laboratory. <italic>Tcrb</italic> - deficient mice were provided by Annette Oxenius (ETH Zurich, Switzerland). CD4<sup>Cre</sup> mice were provided by Burkhard Becher (University of Zurich, Switzerland). CD4<sup>Cre</sup> x STING<sup>flox</sup> and STING<sup>−/−</sup> x OT-I <sup><xref ref-type="bibr" rid="R75">75</xref></sup> x Ly5.1 mice were bred in-house. All strains are on a C57BL/6 background. All mice were housed in individually ventilated cages with wood chip bedding and maintained in a temperature-controlled environment with a 12-hour light/dark cycle under specific pathogen-free (SPF) conditions at the facilities of the Laboratory Animal Services Center (LASC) at the University of Zurich. Mice had access to water (containing 0.5 ppm ClO2) and food <italic>ad libitum</italic>. All experiments were performed with 8-12 weeks-old female mice unless stated otherwise. Experiments were approved by the Cantonal Veterinary Office Zurich under the license numbers ZH37/2021 and ZH38/2021 and conducted according to federal and cantonal regulations.</p></sec><sec id="S16"><title>Cell lines and cell culture</title><p id="P29">LLC cells were purchased from ATCC (CRL-1642). MC38 cells were originally provided by Mark Smyth (QIMR Berghofer Medical Research Institute, Brisbane, Australia). Cell lines were tested negative by PCR for <italic>Mycoplasma ssp.</italic> in-house and for 18 additional mouse pathogens (IMPACT II Test, IDEXX Bioanalytics). Cancer cells were cultured in DMEM (Gibco) supplemented with 10% fetal bovine serum (Gibco), 100 U/mL penicillin, 100 μg/mL streptomycin (Sigma) and 2 mM L-glutamine (Gibco) at 37°C in a humidified atmosphere containing 5% CO2. For counting, cells were diluted 1:100 in 0.4 % Trypan Blue Solution (Gibco) and manually counted using a Neubauer-improved counting chamber. Where indicated, LLC<sup>cGAStetON</sup> cells were cultured with 1 μg/mL DOX and counted after 1 to 4 days.</p></sec></sec><sec id="S17"><title>Method details</title><sec id="S18"><title>Modification of cell lines</title><p id="P30">For the generation of LLC<sup>cGAStetON</sup> cells, murine cGAS-DNA was amplified from the vector pLenti-EF1α-Flag-mm-cGas using Fwd_ArvII-cGAS and Rev_cGAS-MluI primers (Table S1), while adding restriction sites. Amplified DNA was excised and purified from a 1% agarose gel using the NucleoSpin Gel &amp; PCR Clean-up Mini kit (Macherey-Nagel). The target vector (pCW57-GFP-P2A-MCS) and cGAS amplicon were digested with AvrII and MluI-HF. Restricted fragments were purified from a 1% agarose gel and ligated with T4 DNA ligase (Thermo Fisher Scientific). Plasmids were amplified in heat shock-transformed (30 seconds at 42°C) T10 <italic>Escherichia coli</italic> that were grown on agar plates containing ampicillin for selection. Successful cloning was verified by Sanger sequencing of single colonies using the E.coli NightSeq service (Microsynth). Plasmid DNA was purified from liquid bacterium cultures using the ZymoPure II Plasmid Maxiprep kit (Zymo Research). Lentivirus for modification of LLC cells was generated with a second-generation lentiviral packaging system (pMD2.G and pCMV-dR8.91) in HEK 293T cells. A DNA:polyethylenimine (Polysciences) ratio of 1:3 was used for transfection. Lentiviral transduction was performed with 1:5 virus-dilution in DMEM supplemented with 8 μg/mL polybrene (Sigma-Aldrich), followed by 45 minutes of spinoculation at 37°C and 800 <italic>g</italic>. After 48 hours, 500 μg/mL neomycin (InvivoGen) was added to select transduced cells. The DOX-induced expression of cGAS was confirmed by Western blot.</p><p id="P31">For the generation of LLC<sup>cGAStetON-OVA</sup> cells, virus generation and transduction were performed as described above using the pHR OVA/p2a/mCherry-CaaX (Addgene #113030) plasmid. Six days after transduction, cells were sorted for live (Zombie NIR–) mCherry<sup>+</sup> cells.</p><p id="P32">For the generation of LLC<sup>cGAStetON-ΔSTING</sup> cells, single guide (sg) RNAs targeting mouse STING (<italic>Tmem173</italic>) were designed using CRISPOR (<ext-link ext-link-type="uri" xlink:href="http://crispor.gi.ucsc.edu">http://crispor.gi.ucsc.edu</ext-link>) <sup><xref ref-type="bibr" rid="R76">76</xref></sup> (Table S1). SgRNAs were cloned into pSpCas9(BB)-2A-GFP (PX458) (Addgene #48138) after BpiI-mediated restriction. Plasmid amplification and purification were performed as described above. Target cells were transformed using Lipofectamine 3000 (Invitrogen). After 2 days of culture, GFP<sup>+</sup> cells were FACS sorted and expanded. Deficiency of STING was confirmed by Western blot and flow cytometry. The LLC<sup>cGAStetON</sup> model provides significant advantages over stable knock-in/out models, as it avoids unintentional differences caused by the generation of distinct cell lines.</p></sec><sec id="S19"><title><italic>In vivo</italic> experiments</title><p id="P33">Cultured cancer cells were harvested and suspended at 3 x 10<sup>6</sup>/mL in a 2:1 ratio of PBS:Matrigel (Corning). If not stated otherwise, 3 x 10<sup><xref ref-type="bibr" rid="R5">5</xref></sup> cancer cells (100 μL) were injected subcutaneously (s.c.) into the right, previously shaved flank. Unless otherwise specified, cancer-cell-intrinsic cGAS expression was induced by an initial intraperitoneal (i.p.) injection of 50 μg/kg DOX in PBS and subsequent administration of 2 mg/mL DOX + 0.05 mg/mL sucralose in the drinking water for indicated periods. Groups without induction of cGAS expression received PBS i.p. and sucralosecontaining (0.05 mg/mL) drinking water. The tumor size was measured in two dimensions (length and width) using a digital caliper.</p><p id="P34">For T cell depletion, 500 μg of CD4-depleting antibody (clone GK1.5; Rat IgG2a) or CD8-depleting antibody (clone YTS169.4; Rat IgG2a) was injected i.p. Anti-KLH antibody (clone LTF-2; BioXcell) served as an isotype control antibody. After 5 days a second injection was performed, and cell depletion was confirmed in the blood using a CyAn ADP (Beckman Coulter) flow cytometer.</p><p id="P35">For survival studies, a death event was recorded when the tumor size reached 100 mm<sup>2</sup>.</p><p id="P36">For adoptive transfer, CD8<sup>+</sup> T cells were purified from the spleen of age- and sex-matched OT-I mice using the EasySep Mouse CD8<sup>+</sup> T Cell Isolation Kit (STEMCELL Technologies, Cat. #19853) according to the manufacturer’s instructions. The purity of enriched CD8<sup>+</sup> T cells was assessed by flow cytometry and was &gt; 95%. Purified CD8<sup>+</sup> T cells were injected in 200 μL sterile PBS via the tail vein. The number of transferred cells is specified in the individual experiments.</p><p id="P37">For radiotherapy, tumor-bearing mice were randomized based on tumor size immediately before radiotherapy. Radiotherapy was performed as described <sup><xref ref-type="bibr" rid="R45">45</xref></sup>. Briefly, mice were anesthetized by i.p. injection of 50 mg/kg ketamine and 10 mg/kg xylazine. Vitamin A eye ointment was applied to the eyes to prevent dryness during the procedure. Mice were secured in a lead cage to ensure localized irradiation of the tumor with a single dose of 20 Gy using an RS-2000 irradiation unit (Rad Source) with a dose rate of 1.81 Gy/min.</p><p id="P38">In experiments where cGAS expression was induced in established tumors (&gt; day 5), mice were randomized into experimental groups with similar average tumor size and variance before the intervention. Tumors that were palpable but too small to reliably measure were assigned a size of 4 mm<sup>2</sup>.</p></sec><sec id="S20"><title>Tissue collection and processing</title><p id="P39">Tumors and tumor-draining lymph nodes (tdLNs) were excised and collected in RPMI containing 10% FCS. Tumors were manually cut into small pieces and subsequently digested in RPMI containing 10% FCS, 1 mg/mL collagenase IV (Thermo Fisher Scientific), and 50 μg/mL DNase I (Roche) for 45 minutes at 37°C on a rotating device. Digestion was stopped by the addition of 5 mL ice-cold PBS. Digested tumors were passed through a 70-μm cell strainer using the plunger of a 5-mL syringe. Cells were washed with PBS and pelleted by centrifugation at 350 <italic>g</italic> for 5 minutes. Red blood cells were lysed using RBC lysis solution (17 mM Tris pH 7.2, 144 mM NH4Cl) for 2 minutes at room temperature. tdLNs were directly passed through a 70-μm cell strainer and washed with complete RPMI. Blood was collected by submental bleeding in PBS containing 2 mM EDTA.</p></sec><sec id="S21"><title><italic>In vitro</italic> experiments</title><p id="P40">Isolated CD8<sup>+</sup> CD45.1<sup>+</sup> OT-I were labeled with CellTrace Violet (Thermo Fisher Scientific) according to the manufacturer’s instructions. Fifty thousand labeled CD8<sup>+</sup>CD45.1<sup>+</sup> OT-1 STING-deficient or -proficient T cells were co-cultured with the cognate antigen (SIINFEKL), 2 x 10<sup>5</sup> CD45.2<sup>+</sup>STING-deficient splenocytes as antigen-presenting cells and 10 μg/mL cGAMP (or not). Cells were cultured in RPMI containing 10% FCS, 100 U/mL penicillin, 100 μg/mL streptomycin, and 100 U/mL IL- 2 for the period indicated in the figures.</p></sec><sec id="S22"><title>Western blot</title><p id="P41">To extract proteins, cultured cells or tumor tissue were suspended in RIPA buffer (Thermo Fisher Scientific) containing proteinase inhibitor (cOmplete, Mini Protease Inhibitor Cocktail, Roche)). Cells were lysed by pipetting up and down, whereas a handheld homogenizer was used to lyse tumor tissue. Samples were centrifuged at 14,000 <italic>g</italic> for 15 minutes, and protein-containing supernatant was removed. The protein concentration was measured using the DC Protein Assay (Bio-Rad). A total of 20 μg protein was loaded on a 10% SDS PAGE gel. Electrophoresis was performed using a Bio-Rad system at 80 V during the stacking phase for 30 minutes, followed by 120 V for about 1 hour. Proteins were transferred onto a nitrocellulose membrane (GE Healthcare Life Science) with a current of 350 mA for 2 hours at 4°C. The membrane was blocked in 5% non-fat milk powder in Tris-buffered saline containing 0.05% Tween-20 (TBS-T) for 1 hour at room temperature or overnight at 4°C. Membranes were stained with primary antibodies against cGAS (D3O8O, Rabbit mAb #31659, Cell Signaling Technologies, 1:1,000), STING (D2P2F, Rabbit mAb #13647, Cell Signaling Technologies, 1:1,000 dilution) or ß-actin (clone AC-15, mouse monoclonal #A5441, Sigma-Aldrich, 1:5,000 dilution) for 1 hour at room temperature. Primary antibodies were diluted in TBS-T containing 5% non-fat milk powder. Membranes were washed three times for 10 minutes in TBS-T and incubated with the secondary antibodies diluted 1:5,000 in TBS-T containing 5% nonfat milk powder for 1 hour at room temperature. HRP-goat-anti-mouse IgG (Dianova, #111-035-008) and HRP-goat-anti-rabbit IgG (Dianova, #111-035-045) were used as secondary antibodies. Membranes were again washed three times for 10 minutes in TBS-T, and a chemiluminescent reaction was started using the WesternBright ECL-HRP kit (Advansta, K-12045-D20). Protein bands were imaged with a Fusion Solo S imager (Vilber).</p></sec><sec id="S23"><title>Flow cytometry</title><p id="P42">Single-cell suspensions were incubated with anti-CD16/32 antibody in PBS for 5 minutes. Antibody staining of surface molecules was conducted in 50 μL antibody mix in PBS for 30 minutes at 4°C. For intracellular staining, cells were fixed and permeabilized using the Foxp3/Transcription Factor Staining Buffer Set (Invitrogen) for 45 minutes at 4°C according to the manufacturer’s instructions. The antibody mix for staining of intracellular molecules was prepared in 1X permeabilization buffer, and cell suspensions were stained with 50 μL overnight at 4°C. Samples were washed once with 1X permeabilization buffer and once with PBS before acquisition on a Cytek Aurora 5L spectral flow cytometer. Alternatively, LSRFortessa (BD Biosciences) or CyAn ADP (Beckman Coulter) devices were used.</p><p id="P43">Puromycin incorporation, a proxy for metabolic activity <sup><xref ref-type="bibr" rid="R50">50</xref></sup>, was determined by flow cytometry. CD8<sup>+</sup> T cells were resuspended in 100 μL RPMI containing 2% FBS and were rested at 37°C. After 15 minutes, 10 μL puromycin (10 μg/mL in DMSO) was added, and cells were incubated for an additional 40 minutes at 37°C. After incubation, the cells were washed with 150 μL ice-cold PBS. Subsequent staining for flow cytometry was performed as described above. Anti-puromycin antibody was added during the intracellular staining step at a dilution of 1:1,000.</p><p id="P44">FCS files were processed using FlowJo version 10.9. Data from gated populations of interest were exported as compensated FCS files. Preprocessed FCS files were imported into R version 4.2.2. Data were arcsinh transformed and raw marker intensities were quantile normalized to ensure consistent sample comparisons. Subsequent dimensionality reduction was performed using t-distributed Stochastic Neighbor Embedding (t-SNE) or Uniform Manifold Approximation and Projection (UMAP) <sup><xref ref-type="bibr" rid="R77">77</xref></sup>. Cell clusters were identified using unsupervised Rphenograph-clustering <sup><xref ref-type="bibr" rid="R78">78</xref></sup>. Data were visualized using the R package ggplot2. Bioconductor version 3.16 was used for analysis.</p></sec><sec id="S24"><title>Single-cell RNA sequencing</title><p id="P45">Single-cell suspensions from tumors (<italic>n</italic> = 6 per condition) were labeled using the BD Single-Cell Multiplexing Kit (BD) and pooled according to their respective experimental conditions. Intratumoral CD8<sup>+</sup> T cells after adoptive transfer were sorted as single, live CD8<sup>+</sup> using a BD FACSAria III cell sorter. Expression of CD45.1/1 (STING-deficient) or CD45.1/2 (STING-expressing) allowed discrimination and sorting according to T cell STING expression. A total of 40,000 cells per condition were loaded per BD Rhapsody cartridge and processed for cDNA synthesis following the BD Rhapsody Single-Cell Capture and cDNA Synthesis protocol (Doc ID: 23-22951(01)).</p><p id="P46">Library preparation followed the manufacturer’s guidelines outlined in the BD Rhapsody System mRNA Whole Transcriptome Analysis (WTA) and Sample Tag Library Preparation Protocol (Doc ID: 23-24119(02)). Sequencing was conducted on an Illumina NovaSeq X Plus platform following a 150 bp paired-end reads configuration. An average sequencing depth of approximately 50,000 reads per cell was achieved. Data processing, including read alignment, cell barcode demultiplexing, read deduplication, expression matrix generation, and quality reporting, was performed using the Rhapsody Sequence Analysis Pipeline v2.0.</p><p id="P47">Retrieved count matrices were further analyzed using R v4.3.2. Cells were filtered to include only cells with less than 12.5 % mitochondrial gene content. Multiplets were identified and removed using scDblFinder. The Seurat pipeline v5.1 was used for normalization, dimensionality reduction, and clustering. CD8<sup>+</sup> T cells were further cleaned using scGate and UCell-based cluster annotation. Gene set enrichment analysis (GSEA) was conducted using Molecular Signatures Database (MSigDB) gene sets.</p></sec><sec id="S25"><title>Quantification of cGAMP and IFN-β by ELISA</title><p id="P48">For quantification of intra- and extracellular cGAMP in cancer cell lines, cells were seeded in 15-cm culture dishes. For induction of cGAS expression, 1 μg/mL DOX was added. When the cells were 80-90% confluent, the medium was replaced by 5 mL phenol red-free DMEM without additions, except for 1 μg/mL DOX where appropriate. Twenty-four hours later, the conditioned medium was removed and centrifuged at 650 <italic>g</italic> at 4°C for 15 minutes. The supernatant was frozen at −80°C until the assay. The adherent cells were detached with trypsin/EDTA, collected, and centrifuged. Cells were washed once with PBS, centrifuged, and cell pellets were snap-frozen in 1.5-mL reaction tubes using liquid nitrogen for storage at -80°C. Immediately before cGAMP measurement, cell pellets were thawed on ice and lysed using 500 μL M-PER buffer (Thermo Fisher Scientific) per 100 mg cells for 10 minutes, while occasionally vortexing. Cell debris was removed by centrifugation at 14,000 <italic>g</italic> for 15 minutes. For the preparation of tumor tissue, tumor pieces of 100 mg were collected in 500 μL RIPA buffer (Thermo Fisher Scientific) containing proteinase inhibitor (complete, Mini Protease Inhibitor Cocktail, Roche), followed by homogenization with a handheld homogenizer. Homogenized samples were centrifuged at 4°C, 10,000 <italic>g</italic> for 15 minutes followed by collection of the supernatant. Samples were frozen at −80°C until further use. The protein content of lysates was quantified using a DC Protein Assay (Bio-Rad).</p><p id="P49">The concentration of cGAMP in conditioned media, cell- and tumor-lysates was subsequently measured using a cGAMP ELISA (Cayman Chemical) according to the manufacturer’s instructions.</p><p id="P50">The concentration of IFN-β was measured using the VeriKine Mouse IFN-Beta ELISA Kit (PBL Assay Science) according to the manufacturer’s instructions. The signal for protein quantification, cGAMP- and IFN-ß-ELISA was read on a SectraMAX i3 (Molecular Devices).</p></sec><sec id="S26"><title>Statistical analysis</title><p id="P51">One-way or two-way ANOVA was used to compare three or more groups. For comparisons between two groups, either Student’s <italic>t</italic>-test or Mann-Whitney <italic>U</italic>-test was used, depending on data distribution. A <italic>p</italic>- value &lt; 0.05 was considered significant. Statistical analyses were performed using GraphPad Prism software (v9.5.0) or R (v4.3.2).</p></sec><sec id="S27"><title>Key Resources Table</title><table-wrap id="T1" position="anchor" orientation="portrait"><label>Table 1</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle">Reagent or resource Antibodies</th><th align="left" valign="middle">Source</th><th align="left" valign="middle">Identifier</th></tr></thead><tbody><tr><td align="left" valign="middle">Anti-CD4 (clone GK1.5)</td><td align="left" valign="middle">BioXCell</td><td align="left" valign="middle">#BE0003-1 RRID: AB_1107636</td></tr><tr><td align="left" valign="middle">Anti-CD8 (clone YTS 169.4)</td><td align="left" valign="middle">BioXCell</td><td align="left" valign="middle">#BE0117 RRID: AB_10950145</td></tr><tr><td align="left" valign="middle">Anti-KLH (clone LTF-2)</td><td align="left" valign="middle">BioXCell</td><td align="left" valign="middle">#BE0090 RRID: AB_1107780</td></tr><tr><td align="left" valign="middle">Armenian hamster monoclonal anti- CD11c (clone N418) − BV570</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">#117331 RRID: AB_10900261</td></tr><tr><td align="left" valign="middle">Armenian hamster monoclonal anti- CD69 (clone H1.2F3) − PE/Cy5</td><td align="left" valign="middle">eBioscience</td><td align="left" valign="middle">#15-0691-82 RRID: AB_468772</td></tr><tr><td align="left" valign="middle">Armenian hamster monoclonal anti-CD80 (clone 16-10A1) − BV605</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">#104729 RRID: AB_11126141</td></tr><tr><td align="left" valign="middle">Armenian Hamster monoclonal anti-TCRbeta (clone H57-597) − BUV737</td><td align="left" valign="middle">eBioscience</td><td align="left" valign="middle">#367-5961-82 RRID: AB_2896026</td></tr><tr><td align="left" valign="middle">Donkey polyclonal anti-rabbit IgG − Alexa Fluor 488</td><td align="left" valign="middle">Jackson ImmunoResearch</td><td align="left" valign="middle">#711-545-152 RRID: AB_2313584</td></tr><tr><td align="left" valign="middle">H-2Kb/OVA tetramer − BUV421</td><td align="left" valign="middle">Hans Christian Probst (Mainz, Germany)</td><td align="left" valign="middle">N/A</td></tr><tr><td align="left" valign="middle">HRP-goat-anti-mouse IgG</td><td align="left" valign="middle">Dianova</td><td align="left" valign="middle">#111-035-008</td></tr><tr><td align="left" valign="middle">HRP-goat-anti-rabbit IgG</td><td align="left" valign="middle">Dianova</td><td align="left" valign="middle">#111-035-045</td></tr><tr><td align="left" valign="middle">Mouse monoclonal anti-CD366 (TIM-3) (clone 5D12) − BV650</td><td align="left" valign="middle">BD Biosciences</td><td align="left" valign="middle">#747623 RRID: AB_2744189</td></tr><tr><td align="left" valign="middle">Mouse monoclonal anti-CD39 (clone 24DMS1) − PerCP-eFluor 710</td><td align="left" valign="middle">eBioscience</td><td align="left" valign="middle">#46-0391-82 RRID: AB_10717953</td></tr><tr><td align="left" valign="middle">Mouse monoclonal anti-CD4 (clone GK1.5) − BUV496</td><td align="left" valign="middle">BD Biosciences</td><td align="left" valign="middle">#612952 RRID: AB_2870684</td></tr><tr><td align="left" valign="middle">Mouse monoclonal anti-CD45.1 (clone A20) − Pacific Blue</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">#110722 RRID: AB_492866</td></tr><tr><td align="left" valign="middle">Mouse monoclonal anti-CD45.2 (clone 104) − APC</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">#109814 AB_389211</td></tr><tr><td align="left" valign="middle">Mouse monoclonal anti-CD45.2 (clone 104) − FITC</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">#109806 RRID: AB_313443</td></tr><tr><td align="left" valign="middle">Mouse monoclonal anti-CX3CR1 (clone SA011F11) − BV605</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">#149027 RRID: AB_2565937</td></tr><tr><td align="left" valign="middle">Mouse monoclonal anti-FoxP3 (clone 150D) − Alexa Fluor 488</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">#320012 RRID: AB_439748</td></tr><tr><td align="left" valign="middle">Mouse monoclonal anti-Granzyme B (clone QA16A02) − PerCP/Cyanine5.5</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">#372212 RRID: AB_2728379</td></tr><tr><td align="left" valign="middle">Mouse monoclonal anti-Ki-67 (clone B56) − BV480</td><td align="left" valign="middle">BD Biosciences</td><td align="left" valign="middle">#566109 RRID: AB_2739511</td></tr><tr><td align="left" valign="middle">Mouse monoclonal anti-Puromycin (clone 12D10) − Alexa Fluor 488</td><td align="left" valign="middle">Merck</td><td align="left" valign="middle">MABE343-AF488 RRID: AB_273675</td></tr><tr><td align="left" valign="middle">Mouse monoclonal anti-T-bet (clone 4B10) − BV711</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">#644820 RRID: AB_2715766</td></tr><tr><td align="left" valign="middle">Mouse monoclonal anti-XCR1 (clone ZET) − BV510</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">#148218 RRID: AB_2565231</td></tr><tr><td align="left" valign="middle">Mouse monoclonal anti-ß-Actin (clone AC-15)</td><td align="left" valign="middle">Sigma-Aldrich</td><td align="left" valign="middle">#A5441 RRID: AB_476744</td></tr><tr><td align="left" valign="middle">Rabbit monoclonal anti- cGAS (clone D3O8O)</td><td align="left" valign="middle">Cell Signaling Technologies</td><td align="left" valign="middle">#31659 RRID: AB_2799008</td></tr><tr><td align="left" valign="middle">Rabbit monoclonal anti-STING (clone D2P2F)</td><td align="left" valign="middle">Cell Signaling Technologies</td><td align="left" valign="middle">#13647 RRID: AB_2732796</td></tr><tr><td align="left" valign="middle">Rabbit monoclonal anti-TCF1/TCF7 (clone C63D9) − Alexa Fluor 647</td><td align="left" valign="middle">Cell Signaling Technologies</td><td align="left" valign="middle">#6709 RRID: AB_2797631</td></tr><tr><td align="left" valign="middle">Rabbit polyclonal anti-STING</td><td align="left" valign="middle">Proteintech</td><td align="left" valign="middle">#19851-1-AP RRID: AB_10665370</td></tr><tr><td align="left" valign="middle">Rat monoclonal anti-CD11b (clone M1/70) − BUV661</td><td align="left" valign="middle">eBioscience</td><td align="left" valign="middle">#367-0112-82 RRID: AB_2869708</td></tr><tr><td align="left" valign="middle">Rat monoclonal anti-CD16/32 (clone 93)</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">#101302 RRID: AB_312801</td></tr><tr><td align="left" valign="middle">Rat monoclonal anti-CD223 (LAG-3) (clone C9B7W) − BUV395</td><td align="left" valign="middle">BD Biosciences</td><td align="left" valign="middle">#745693 RRID: AB_2743177</td></tr><tr><td align="left" valign="middle">Rat monoclonal anti-CD25 (clone PC61) −BV650</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">#102038 RRID: AB_2563060</td></tr><tr><td align="left" valign="middle">Rat monoclonal anti-CD274 (B7-H1, PD-L1) (clone MIH6) − FITC</td><td align="left" valign="middle">Bio-Rad</td><td align="left" valign="middle">#MCA2626F</td></tr><tr><td align="left" valign="middle">Rat monoclonal anti-CD279 (PD-1) (clone 29F.1A12) − BV785</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">#135225 RRID: AB_2563680</td></tr><tr><td align="left" valign="middle">Rat monoclonal anti-CD40 (clone 3/23) −APC</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">#124612 RRID: AB_1134072</td></tr><tr><td align="left" valign="middle">Rat monoclonal anti-CD44 (clone IM7) − PE/Cy7</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">#103030 RRID: AB_830787</td></tr><tr><td align="left" valign="middle">Rat monoclonal anti-CD45 (clone 30- F11) − BUV563</td><td align="left" valign="middle">BD Biosciences</td><td align="left" valign="middle">#612924 RRID: AB_2722550</td></tr><tr><td align="left" valign="middle">Rat monoclonal anti-CD62L (clone MEL-14) −BV570</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">#104433 RRID: AB_10900262</td></tr><tr><td align="left" valign="middle">Rat monoclonal anti-CD70 (clone FR70) − PE/Cyanine7</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">#104612 RRID: AB_2750467</td></tr><tr><td align="left" valign="middle">Rat monoclonal anti-CD86 (clone GL- 1) − PE/Cyanine5</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">#105016 RRID: AB_493602</td></tr><tr><td align="left" valign="middle">Rat monoclonal anti-CD8a (clone 53-6.7) − BUV805</td><td align="left" valign="middle">eBioscience</td><td align="left" valign="middle">#368-0081-82 RRID: AB_2896078</td></tr><tr><td align="left" valign="middle">Rat monoclonal anti-EOMES (clone Dan11mag) − PE-eFluor610</td><td align="left" valign="middle">eBioscience</td><td align="left" valign="middle">#61-4875-82 RRID: AB_2574614</td></tr><tr><td align="left" valign="middle">Rat monoclonal anti-F4/80 (clone BM8) − PE</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">#123110 RRID: AB_893486</td></tr><tr><td align="left" valign="middle">Rat monoclonal anti-Ly-6C (clone HK1.4) − BV711</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">#128037 RRID: AB_2562630</td></tr><tr><td align="left" valign="middle">Rat monoclonal anti-Ly-6G (clone 1A8) − BV785</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">#127645 RRID: AB_2566317</td></tr><tr><td align="left" valign="middle">Recombinant monoclonal anti-TOX</td><td align="left" valign="middle">Miltenyi Biotec</td><td align="left" valign="middle">#130-120-716</td></tr><tr><td align="left" valign="middle">(clone REA473) −PE</td><td align="left" valign="middle"/><td align="left" valign="middle">RRID: AB_2801785</td></tr><tr><td align="left" valign="middle">Syrian Hamster monoclonal anti- KLRG1 (clone 2F1) − BUV615</td><td align="left" valign="middle">BD Biosciences</td><td align="left" valign="middle">#751191 RRID: AB_2875213</td></tr><tr style="background-color:#d9d9d9"><td align="left" valign="middle"><bold>Chemicals, peptides, and recombinant proteins</bold></td></tr><tr><td align="left" valign="middle">0.4 % Trypan Blue Solution</td><td align="left" valign="middle">Gibco</td><td align="left" valign="middle">15250061</td></tr><tr><td align="left" valign="middle">2’3’-cGAMP</td><td align="left" valign="middle">InVivogen</td><td align="left" valign="middle">tlrl-nacga23-1</td></tr><tr><td align="left" valign="middle">30% Acrylamide/Bis Solution</td><td align="left" valign="middle">Bio-Rad</td><td align="left" valign="middle">#1610156</td></tr><tr><td align="left" valign="middle">Albumin Standard</td><td align="left" valign="middle">Thermo Fisher Scientific</td><td align="left" valign="middle">#23209</td></tr><tr><td align="left" valign="middle">Ammonium Persulfate</td><td align="left" valign="middle">Bio-Rad</td><td align="left" valign="middle">#1610700</td></tr><tr><td align="left" valign="middle">AvrII</td><td align="left" valign="middle">New England Biolabs (NEB)</td><td align="left" valign="middle">R0174S</td></tr><tr><td align="left" valign="middle">CellTrace Violet</td><td align="left" valign="middle">Thermo Fisher Scientific</td><td align="left" valign="middle">C34557</td></tr><tr><td align="left" valign="middle">Collagenase Type IV</td><td align="left" valign="middle">Thermo Fisher Scientific</td><td align="left" valign="middle">17104019</td></tr><tr><td align="left" valign="middle">cOmplete Protease Inhibitor Cocktail</td><td align="left" valign="middle">Roche</td><td align="left" valign="middle">11836170001</td></tr><tr><td align="left" valign="middle">D(+)Saccharose</td><td align="left" valign="middle">Carl Roth</td><td align="left" valign="middle">9097.2</td></tr><tr><td align="left" valign="middle">DMEM medium</td><td align="left" valign="middle">Gibco</td><td align="left" valign="middle">11965092</td></tr><tr><td align="left" valign="middle">DNAse I</td><td align="left" valign="middle">Roche</td><td align="left" valign="middle">10104159001</td></tr><tr><td align="left" valign="middle">DNaseI reaction buffer (10X)</td><td align="left" valign="middle">New England Biolabs (NEB)</td><td align="left" valign="middle">B0303S</td></tr><tr><td align="left" valign="middle">DPBS</td><td align="left" valign="middle">Gibco</td><td align="left" valign="middle">14190144</td></tr><tr><td align="left" valign="middle">Ethanol absolute</td><td align="left" valign="middle">VWR Chemicals</td><td align="left" valign="middle">20821.321</td></tr><tr><td align="left" valign="middle">FastDigest BpiI</td><td align="left" valign="middle">Thermo Fisher Scientific</td><td align="left" valign="middle">FD1014</td></tr><tr><td align="left" valign="middle">FastDigest Green Buffer (10X)</td><td align="left" valign="middle">Thermo Fisher Scientific</td><td align="left" valign="middle">FD1014</td></tr><tr><td align="left" valign="middle">Fetal Bovine Serum (FBS)</td><td align="left" valign="middle">Gibco</td><td align="left" valign="middle">A5256701</td></tr><tr><td align="left" valign="middle">GENEzol</td><td align="left" valign="middle">Geneaid Biotech</td><td align="left" valign="middle">GZR200</td></tr><tr><td align="left" valign="middle">Kapa Probe Fast Universal</td><td align="left" valign="middle">Kapa Biosystems</td><td align="left" valign="middle">KK4701</td></tr><tr><td align="left" valign="middle">L-Glutamine (200 mM)</td><td align="left" valign="middle">Gibco</td><td align="left" valign="middle">25030081</td></tr><tr><td align="left" valign="middle">Lipofectamine 3000</td><td align="left" valign="middle">Invitrogen</td><td align="left" valign="middle">L3000001</td></tr><tr><td align="left" valign="middle">Matrigel Basement Membrane Matrix</td><td align="left" valign="middle">Corning</td><td align="left" valign="middle">354234</td></tr><tr><td align="left" valign="middle">MluI-HF</td><td align="left" valign="middle">New England Biolabs (NEB)</td><td align="left" valign="middle">R3198S</td></tr><tr><td align="left" valign="middle">Mouse IL-2 Carrier-Free Recombinant Protein</td><td align="left" valign="middle">eBioscience</td><td align="left" valign="middle">34-8021-85</td></tr><tr><td align="left" valign="middle">MultiScribe Reverse Transcriptase</td><td align="left" valign="middle">Thermo Fisher Scientific</td><td align="left" valign="middle">4311235</td></tr><tr><td align="left" valign="middle">Neomycin (G418)</td><td align="left" valign="middle">InvivoGen</td><td align="left" valign="middle">ant-gn-2</td></tr><tr><td align="left" valign="middle">Polybrene Infection / Transfection Reagent</td><td align="left" valign="middle">Sigma-Aldrich</td><td align="left" valign="middle">TR-1003</td></tr><tr><td align="left" valign="middle">Polyethylenimine (PEI)</td><td align="left" valign="middle">Polysciences</td><td align="left" valign="middle">23966-1</td></tr><tr><td align="left" valign="middle">PowerUp SYBR Green Master Mix</td><td align="left" valign="middle">Applied Biosystems</td><td align="left" valign="middle">A25742</td></tr><tr><td align="left" valign="middle">Puromycin dihydrochloride</td><td align="left" valign="middle">Sigma-Aldrich</td><td align="left" valign="middle">P7255</td></tr><tr><td align="left" valign="middle">rCutSmart Buffer</td><td align="left" valign="middle">New England Biolabs (NEB)</td><td align="left" valign="middle">B6004S</td></tr><tr><td align="left" valign="middle">RIPA Lysis and Extraction Buffer</td><td align="left" valign="middle">Thermo Fisher Scientific</td><td align="left" valign="middle">89900</td></tr><tr><td align="left" valign="middle">RNase Inhibitor</td><td align="left" valign="middle">Applied Biosystems</td><td align="left" valign="middle">N8080119</td></tr><tr><td align="left" valign="middle">RPMI 1640 medium</td><td align="left" valign="middle">Gibco</td><td align="left" valign="middle">21875034</td></tr><tr><td align="left" valign="middle">Sucralose (≥98% (HPLC))</td><td align="left" valign="middle">Sigma-Aldrich</td><td align="left" valign="middle">69293</td></tr><tr><td align="left" valign="middle">T4 DNA ligase</td><td align="left" valign="middle">Thermo Fisher Scientific</td><td align="left" valign="middle">EL0011</td></tr><tr><td align="left" valign="middle">T4 DNA Ligase Buffer (10X)</td><td align="left" valign="middle">Thermo Fisher Scientific</td><td align="left" valign="middle">B69</td></tr><tr><td align="left" valign="middle">T4 Polynucleotide Kinase</td><td align="left" valign="middle">New England Biolabs (NEB)</td><td align="left" valign="middle">M0201S</td></tr><tr><td align="left" valign="middle">T4 Polynucleotide Kinase Reaction Buffer (10X)</td><td align="left" valign="middle">New England Biolabs (NEB)</td><td align="left" valign="middle">B0201S</td></tr><tr><td align="left" valign="middle">TEMED</td><td align="left" valign="middle">Bio-Rad</td><td align="left" valign="middle">#1610800</td></tr><tr><td align="left" valign="middle">Tween 20</td><td align="left" valign="middle">Sigma-Aldrich</td><td align="left" valign="middle">P1379</td></tr><tr><td align="left" valign="middle">UltraComp eBeads Plus Compensation Beads</td><td align="left" valign="middle">Invitrogen</td><td align="left" valign="middle">01-3333-42</td></tr><tr><td align="left" valign="middle">Zombie NIR Fixable Viability Kit</td><td align="left" valign="middle">BioLegend</td><td align="left" valign="middle">423106</td></tr><tr style="background-color:#d9d9d9"><td align="left" valign="middle"><bold>Recombinant DNA</bold></td></tr><tr><td align="left" valign="middle">pCMV-dR8.91</td><td align="left" valign="middle">Christian Münz, Zürich, Switzerland</td><td align="left" valign="middle">N/A</td></tr><tr><td align="left" valign="middle">pCW57-GFP-P2A-MCS</td><td align="left" valign="middle">Addgene</td><td align="left" valign="middle">#71783</td></tr><tr><td align="left" valign="middle">pHR OVA/p2a/mCherry-CaaX</td><td align="left" valign="middle">Addgene</td><td align="left" valign="middle">#113030</td></tr><tr><td align="left" valign="middle">pLenti-EF1α-Flag-mm-cGas</td><td align="left" valign="middle">Winfried Barchet, Bonn, Germany</td><td align="left" valign="middle">N/A</td></tr><tr><td align="left" valign="middle">pMD2.G</td><td align="left" valign="middle">Addgene</td><td align="left" valign="middle">#12259</td></tr><tr><td align="left" valign="middle">pSpCas9(BB)-2A-GFP (PX458)</td><td align="left" valign="middle">Addgene</td><td align="left" valign="middle">#48138</td></tr><tr style="background-color:#d9d9d9"><td align="left" valign="middle"><bold>Experimental models: Organisms/strains</bold></td></tr><tr><td align="left" valign="middle">C57BL/6NRj</td><td align="left" valign="middle">Janvier</td><td align="left" valign="middle">027</td></tr><tr><td align="left" valign="middle">CD4<sup>Cre</sup> (STOCK Tg(Cd4-cre)1Cwi/BfluJ)</td><td align="left" valign="middle">Provided by Burkhard Becher, Zürich</td><td align="left" valign="middle">RRID: IMSR_JAX: 017336</td></tr><tr><td align="left" valign="middle">Mx1<sup>gfp</sup> (B6.Cg-<italic>Mx1<sup>tm1·1Agsa</sup></italic> /J)</td><td align="left" valign="middle">The Jackson Laboratory</td><td align="left" valign="middle">RRID: IMSR_JAX: 033219</td></tr><tr><td align="left" valign="middle">STING<sup>−/−</sup>(C57BL/6J-<italic>Sting1<sup>gt</sup>/J</italic>)</td><td align="left" valign="middle">The Jackson Laboratory</td><td align="left" valign="middle">RRID: IMSR_JAX: 017537</td></tr><tr><td align="left" valign="middle">STING<sup>flox</sup> (B6;SJL- <italic>Sting1<sup>tm1.1Camb</sup></italic>/J)</td><td align="left" valign="middle">The Jackson Laboratory</td><td align="left" valign="middle">RRID: IMSR_JAX: 031670</td></tr><tr><td align="left" valign="middle">Tcrb KO (B6.129P2-<italic>Tcrb<sup>tm1Mom</sup></italic>/J)</td><td align="left" valign="middle">Provided by Annette Oxenius, Zürich</td><td align="left" valign="middle">RRID: IMSR_JAX: 002118</td></tr><tr style="background-color:#d9d9d9"><td align="left" valign="middle"><bold>Critical commercial assays</bold></td></tr><tr><td align="left" valign="middle">2’3’-cGAMP ELISA</td><td align="left" valign="middle">Cayman Chemical</td><td align="left" valign="middle">501700</td></tr><tr><td align="left" valign="middle">BD Rhapsody cDNA Kit</td><td align="left" valign="middle">BD Biosciences</td><td align="left" valign="middle">633773</td></tr><tr><td align="left" valign="middle">BD Rhapsody WTA Amplification Kit</td><td align="left" valign="middle">BD Biosciences</td><td align="left" valign="middle">633801</td></tr><tr><td align="left" valign="middle">DC Protein Assay Kit I</td><td align="left" valign="middle">Bio-Rad</td><td align="left" valign="middle">5000111</td></tr><tr><td align="left" valign="middle">EasySep Mouse CD8<sup>+</sup> T Cell Isolation Kit</td><td align="left" valign="middle">Stemcell Technologies</td><td align="left" valign="middle">19853</td></tr><tr><td align="left" valign="middle">Foxp3 / Transcription Factor Staining Buffer Set</td><td align="left" valign="middle">Invitrogen</td><td align="left" valign="middle">00-5523-00</td></tr><tr><td align="left" valign="middle">High-Capacity cDNA Reverse Transcription Kit</td><td align="left" valign="middle">Applied Biosystems</td><td align="left" valign="middle">4368813</td></tr><tr><td align="left" valign="middle">Mouse IFN-Beta ELISA</td><td align="left" valign="middle">PBL Assay Science</td><td align="left" valign="middle">42410</td></tr><tr><td align="left" valign="middle">NucleoSpin Gel&amp; PCR Clean-up Mini kit</td><td align="left" valign="middle">Macherey-Nagel</td><td align="left" valign="middle">740609</td></tr><tr><td align="left" valign="middle">Rhapsody Cartridge Kit</td><td align="left" valign="middle">BD Biosciences</td><td align="left" valign="middle">633733</td></tr><tr><td align="left" valign="middle">Rhapsody Enhanced Cartridge Reagent Kit</td><td align="left" valign="middle">BD Biosciences</td><td align="left" valign="middle">664887</td></tr><tr><td align="left" valign="middle">Single-Cell Sample Multiplexing Kit</td><td align="left" valign="middle">BD Biosciences</td><td align="left" valign="middle">633793</td></tr><tr><td align="left" valign="middle">ZymoPure II Plasmid Maxiprep kit</td><td align="left" valign="middle">Zymo Research</td><td align="left" valign="middle">D4203</td></tr><tr style="background-color:#d9d9d9"><td align="left" valign="middle"><bold>Experimental models: Cell Lines</bold></td></tr><tr><td align="left" valign="middle">MC38</td><td align="left" valign="middle">Mark Smyth, Brisbane, Australia</td><td align="left" valign="middle">N/A</td></tr><tr><td align="left" valign="middle">LLC</td><td align="left" valign="middle">ATCC</td><td align="left" valign="middle">CRL-1642</td></tr><tr><td align="left" valign="middle">LLC<sup>OVA-mCherry</sup></td><td align="left" valign="middle">This paper, Referred to as LLC<sup>OVA</sup></td><td align="left" valign="middle">N/A</td></tr><tr><td align="left" valign="middle">LLC<sup>cGAStetON</sup></td><td align="left" valign="middle">This paper</td><td align="left" valign="middle">N/A</td></tr><tr><td align="left" valign="middle">LLC<sup>cG AStetON-Δ-mCherry</sup></td><td align="left" valign="middle">This paper, Referred to as LLC<sup>cGAStetON-STING-OVA</sup></td><td align="left" valign="middle">N/A</td></tr><tr><td align="left" valign="middle">LLQ<sup>cGAStetON-SIING</sup></td><td align="left" valign="middle">This paper</td><td align="left" valign="middle">N/A</td></tr><tr><td align="left" valign="middle">LLC<sup>cGAStetON-ΔSTING-OVA-mCherry</sup></td><td align="left" valign="middle">This paper, Referred to as LLC<sup>cGAStetON-</sup>δsting-ova</td><td align="left" valign="middle">N/A</td></tr><tr><td align="left" valign="middle">HEK 293T</td><td align="left" valign="middle">ATCC</td><td align="left" valign="middle">CRL-3216</td></tr><tr style="background-color:#d9d9d9"><td align="left" valign="middle"><bold>Bacterial and virus strains</bold></td></tr><tr><td align="left" valign="middle">NEB Stable Competent <italic>E. coli</italic> (High Efficiency)</td><td align="left" valign="middle">New England Biolabs (NEB)</td><td align="left" valign="middle">C3040</td></tr><tr><td align="left" valign="middle">TOP10 Chemically Competent <italic>E. coli</italic></td><td align="left" valign="middle">Thermo Fisher Scientific</td><td align="left" valign="middle">C404010</td></tr><tr style="background-color:#d9d9d9"><td align="left" valign="middle"><bold>Software and algorithms</bold></td></tr><tr><td align="left" valign="middle">GraphPad Prism (v9.5.0)</td><td align="left" valign="middle">GraphPad</td><td align="left" valign="middle"><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/">https://www.graphpad.com/</ext-link></td></tr><tr><td align="left" valign="middle">FlowJo (v10.9.0)</td><td align="left" valign="middle">BD Biosciences</td><td align="left" valign="middle"><ext-link ext-link-type="uri" xlink:href="https://www.flowjo.com">https://www.flowjo.com</ext-link></td></tr><tr><td align="left" valign="middle">R (v4.3.2)</td><td align="left" valign="middle">R Foundation for Statistical Computing</td><td align="left" valign="middle"><ext-link ext-link-type="uri" xlink:href="https://www.r-project.org/">https://www.r-project.org/</ext-link></td></tr><tr><td align="left" valign="middle">RStudio (v2022.12.0)</td><td align="left" valign="middle">Posit, PBC</td><td align="left" valign="middle"><ext-link ext-link-type="uri" xlink:href="https://posit.co/download/rstudio/">https://posit.co/download/rstudio/</ext-link></td></tr><tr style="background-color:#d9d9d9"><td align="left" valign="middle"><bold>Other</bold></td></tr><tr><td align="left" valign="middle">70 μm Cell Strainers</td><td align="left" valign="middle">Biologix</td><td align="left" valign="middle">15-1070-2</td></tr><tr><td align="left" valign="middle">Aurora 5L</td><td align="left" valign="middle">Cytek Biosciences</td><td align="left" valign="middle">N/A</td></tr><tr><td align="left" valign="middle">CyAn ADP</td><td align="left" valign="middle">Beckman Coulter</td><td align="left" valign="middle">N/A</td></tr><tr><td align="left" valign="middle">FACS Aria III cell sorter</td><td align="left" valign="middle">BD Biosciences</td><td align="left" valign="middle">N/A</td></tr><tr><td align="left" valign="middle">Insulin syringe 0.5 mL</td><td align="left" valign="middle">Braun</td><td align="left" valign="middle">9151125S</td></tr><tr><td align="left" valign="middle">LightCycler 480 II</td><td align="left" valign="middle">Roche Diagnostics</td><td align="left" valign="middle">N/A</td></tr><tr><td align="left" valign="middle">LSRFortessa</td><td align="left" valign="middle">BD Biosciences</td><td align="left" valign="middle">N/A</td></tr><tr><td align="left" valign="middle">RS 2000 Small Animal Irradiator</td><td align="left" valign="middle">Rad Source Technologies</td><td align="left" valign="middle">N/A</td></tr><tr><td align="left" valign="middle">SectraMAX i3</td><td align="left" valign="middle">Molecular Devices</td><td align="left" valign="middle">N/A</td></tr></tbody></table></table-wrap></sec></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Material</label><media xlink:href="EMS199802-supplement-Supplementary_Material.pdf" mimetype="application" mime-subtype="pdf" id="d23aAcEbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S28"><title>Acknowledgements</title><p>This work was supported by the University Research Priority Program “Translational Cancer Research” (University of Zurich; MvdB), SKINTEGRITY.ch (University of Zurich; MvdB), the Hartmann-Müller-Foundation (MH), the Swiss National Science Foundation (310030_208145 MvdB), the Stiftung für Krebsbekämpfung Zurich (MvdB) and the Novartis Foundation for medical-biological Research (24A054; MvdB). The authors thank the personnel of the Laboratory Animal Services Center (LASC, University of Zurich) for expert animal care. We thank Tatiane Gorski (Cytometry Facility, University of Zurich) and Hubert Rehrauer (Functional Genomic Center Zurich) for help with scRNA-sequencing, and Ulrich Kalinke (Twincore, Hannover, Germany) and Hans Christian Probst (University of Mainz, Germany) for discussion.</p></ack><sec id="S29" sec-type="data-availability"><title>Data and code availability</title><p id="P52">
<list list-type="bullet" id="L1"><list-item><p id="P53">All data reported in this paper will be shared by the lead contact upon reasonable request.</p></list-item><list-item><p id="P54">This paper does not report an original code.</p></list-item><list-item><p id="P55">Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon reasonable request.</p></list-item></list></p></sec><fn-group><fn id="FN1" fn-type="con"><p id="P56"><bold>Author contributions</bold></p><p id="P57">MH and MvdB conceived the experiments and wrote the manuscript; MH, HK, SB, DZ, ID and VDS performed the experiments. PP and VC performed sorting. MH, HK, and MN analyzed the data. MvdB secured funding; All the authors reviewed the results and approved the final manuscript.</p></fn><fn id="FN2"><p id="P58"><bold>Declaration of interests</bold></p><p id="P59">The authors declare no competing interests.</p></fn><fn id="FN3"><p id="P60"><bold>Ethical approval statement</bold></p><p id="P61">Mouse experiments were performed according to Swiss cantonal and federal regulations on animal protection and approved by the cantonal veterinary office of Zürich under license numbers 37/2021 (33442) and 38/2021 (33443).</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Type I interferon is selectively required by dendritic cells for immune rejection of tumors</article-title><source>Journal of Experimental Medicine</source><year>2011</year><volume>208</volume><fpage>1989</fpage><lpage>2003</lpage><pub-id pub-id-type="pmcid">PMC3182061</pub-id><pub-id pub-id-type="pmid">21930769</pub-id><pub-id pub-id-type="doi">10.1084/jem.20101158</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>SR</given-names></name><etal/></person-group><article-title>STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors</article-title><source>Immunity</source><year>2014</year><volume>41</volume><fpage>830</fpage><lpage>842</lpage><pub-id pub-id-type="pmcid">PMC4384884</pub-id><pub-id pub-id-type="pmid">25517615</pub-id><pub-id pub-id-type="doi">10.1016/j.immuni.2014.10.017</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuertes</surname><given-names>MB</given-names></name><etal/></person-group><article-title>Host type I IFN signals are required for antitumor CD8<sup>+</sup> T cell responses through CD8α+ dendritic cells</article-title><source>Journal of Experimental Medicine</source><year>2011</year><volume>208</volume><fpage>2005</fpage><lpage>2016</lpage><pub-id pub-id-type="pmcid">PMC3182064</pub-id><pub-id pub-id-type="pmid">21930765</pub-id><pub-id pub-id-type="doi">10.1084/jem.20101159</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name></person-group><article-title>Tumor microenvironment and therapeutic response</article-title><source>Cancer Lett</source><year>2017</year><volume>387</volume><fpage>61</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">26845449</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Du</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>ZJ</given-names></name></person-group><article-title>Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway</article-title><source>Science (1979)</source><year>2013</year><volume>339</volume><fpage>786</fpage><lpage>791</lpage><pub-id pub-id-type="pmcid">PMC3863629</pub-id><pub-id pub-id-type="pmid">23258413</pub-id><pub-id pub-id-type="doi">10.1126/science.1232458</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA</article-title><source>Science (1979)</source><year>2013</year><volume>339</volume><fpage>826</fpage><lpage>830</lpage><pub-id pub-id-type="pmcid">PMC3855410</pub-id><pub-id pub-id-type="pmid">23258412</pub-id><pub-id pub-id-type="doi">10.1126/science.1229963</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ablasser</surname><given-names>A</given-names></name><etal/></person-group><article-title>CGAS produces a 2’-5’-linked cyclic dinucleotide second messenger that activates STING</article-title><source>Nature</source><year>2013</year><volume>498</volume><fpage>380</fpage><lpage>384</lpage><pub-id pub-id-type="pmcid">PMC4143541</pub-id><pub-id pub-id-type="pmid">23722158</pub-id><pub-id pub-id-type="doi">10.1038/nature12306</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diner</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>The Innate Immune DNA Sensor cGAS Produces a Noncanonical Cyclic Dinucleotide that Activates Human STING</article-title><source>Cell Rep</source><year>2013</year><volume>3</volume><fpage>1355</fpage><lpage>1361</lpage><pub-id pub-id-type="pmcid">PMC3706192</pub-id><pub-id pub-id-type="pmid">23707065</pub-id><pub-id pub-id-type="doi">10.1016/j.celrep.2013.05.009</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>P</given-names></name><etal/></person-group><article-title>Cyclic [G(2’,5’)pA(3’,5’)p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase</article-title><source>Cell</source><year>2013</year><volume>153</volume><fpage>1094</fpage><lpage>1107</lpage><pub-id pub-id-type="pmcid">PMC4382009</pub-id><pub-id pub-id-type="pmid">23647843</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2013.04.046</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Cyclic GMP-AMP Containing Mixed Phosphodiester Linkages Is An Endogenous High-Affinity Ligand for STING</article-title><source>Mol Cell</source><year>2013</year><volume>51</volume><fpage>226</fpage><lpage>235</lpage><pub-id pub-id-type="pmcid">PMC3808999</pub-id><pub-id pub-id-type="pmid">23747010</pub-id><pub-id pub-id-type="doi">10.1016/j.molcel.2013.05.022</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burdette</surname><given-names>DL</given-names></name><etal/></person-group><article-title>STING is a direct innate immune sensor of cyclic di-GMP</article-title><source>Nature</source><year>2011</year><volume>478</volume><fpage>515</fpage><lpage>518</lpage><comment>2011 478:7370</comment><pub-id pub-id-type="pmcid">PMC3203314</pub-id><pub-id pub-id-type="pmid">21947006</pub-id><pub-id pub-id-type="doi">10.1038/nature10429</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishikawa</surname><given-names>H</given-names></name><name><surname>Barber</surname><given-names>GN</given-names></name></person-group><article-title>STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling</article-title><source>Nature</source><year>2008</year><volume>455</volume><fpage>674</fpage><lpage>678</lpage><pub-id pub-id-type="pmcid">PMC2804933</pub-id><pub-id pub-id-type="pmid">18724357</pub-id><pub-id pub-id-type="doi">10.1038/nature07317</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saitoh</surname><given-names>T</given-names></name><etal/></person-group><article-title>Atg9a controls dsDNA-driven dynamic translocation of STING and the innate immune response</article-title><source>Proc Natl Acad Sci U S A</source><year>2009</year><volume>106</volume><fpage>20842</fpage><lpage>20846</lpage><pub-id pub-id-type="pmcid">PMC2791563</pub-id><pub-id pub-id-type="pmid">19926846</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0911267106</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>ZJ</given-names></name></person-group><article-title>STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway</article-title><source>Sci Signal</source><year>2012</year><volume>5</volume><pub-id pub-id-type="pmcid">PMC3549669</pub-id><pub-id pub-id-type="pmid">22394562</pub-id><pub-id pub-id-type="doi">10.1126/scisignal.2002521</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation</article-title><source>Science (1979)</source><year>2015</year><volume>347</volume><comment>aaa2630-aaa2630</comment><pub-id pub-id-type="pmid">25636800</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Au</surname><given-names>WC</given-names></name><name><surname>Moore</surname><given-names>PA</given-names></name><name><surname>Lowther</surname><given-names>W</given-names></name><name><surname>Juang</surname><given-names>YT</given-names></name><name><surname>Pitha</surname><given-names>PM</given-names></name></person-group><article-title>Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes</article-title><source>Proc Natl Acad Sci U S A</source><year>1995</year><volume>92</volume><elocation-id>11657</elocation-id><pub-id pub-id-type="pmcid">PMC40461</pub-id><pub-id pub-id-type="pmid">8524823</pub-id><pub-id pub-id-type="doi">10.1073/pnas.92.25.11657</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>ZJ</given-names></name></person-group><article-title>The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer</article-title><source>Journal of Experimental Medicine</source><year>2018</year><volume>215</volume><fpage>1287</fpage><lpage>1299</lpage><pub-id pub-id-type="pmcid">PMC5940270</pub-id><pub-id pub-id-type="pmid">29622565</pub-id><pub-id pub-id-type="doi">10.1084/jem.20180139</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>GP</given-names></name><name><surname>Koebel</surname><given-names>CM</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name></person-group><article-title>Transformation Interferons, immunity and cancer immunoediting</article-title><year>2006</year><pub-id pub-id-type="pmid">17063185</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schadt</surname><given-names>L</given-names></name><etal/></person-group><article-title>Cancer-Cell-Intrinsic cGAS Expression Mediates Tumor Immunogenicity</article-title><source>Cell Rep</source><year>2019</year><volume>29</volume><fpage>1236</fpage><lpage>1248</lpage><elocation-id>e7</elocation-id><pub-id pub-id-type="pmid">31665636</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ablasser</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP</article-title><source>Nature</source><year>2013</year><volume>503</volume><fpage>530</fpage><lpage>534</lpage><pub-id pub-id-type="pmcid">PMC4142317</pub-id><pub-id pub-id-type="pmid">24077100</pub-id><pub-id pub-id-type="doi">10.1038/nature12640</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carozza</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Extracellular cGAMP is a cancer-cell-produced immunotransmitter involved in radiation-induced anticancer immunity</article-title><source>Nat Cancer</source><year>2020</year><volume>1</volume><fpage>184</fpage><lpage>196</lpage><pub-id pub-id-type="pmcid">PMC7990037</pub-id><pub-id pub-id-type="pmid">33768207</pub-id><pub-id pub-id-type="doi">10.1038/s43018-020-0028-4</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luteijn</surname><given-names>RD</given-names></name><etal/></person-group><article-title>SLC19A1 transports immunoreactive cyclic dinucleotides</article-title><source>Nature</source><year>2019</year><volume>573</volume><fpage>434</fpage><lpage>438</lpage><pub-id pub-id-type="pmcid">PMC6785039</pub-id><pub-id pub-id-type="pmid">31511694</pub-id><pub-id pub-id-type="doi">10.1038/s41586-019-1553-0</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>C</given-names></name><name><surname>Cordova</surname><given-names>AF</given-names></name><name><surname>Hess</surname><given-names>GT</given-names></name><name><surname>Bassik</surname><given-names>MC</given-names></name><name><surname>Li</surname><given-names>L</given-names></name></person-group><article-title>SLC19A1 Is an Importer of the Immunotransmitter cGAMP</article-title><source>Mol Cell</source><year>2019</year><volume>75</volume><fpage>372</fpage><lpage>381</lpage><elocation-id>e5</elocation-id><pub-id pub-id-type="pmcid">PMC6711396</pub-id><pub-id pub-id-type="pmid">31126740</pub-id><pub-id pub-id-type="doi">10.1016/j.molcel.2019.05.006</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcus</surname><given-names>A</given-names></name><etal/></person-group><article-title>Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response</article-title><source>Immunity</source><year>2018</year><volume>49</volume><fpage>754</fpage><lpage>763</lpage><elocation-id>e4</elocation-id><pub-id pub-id-type="pmcid">PMC6488306</pub-id><pub-id pub-id-type="pmid">30332631</pub-id><pub-id pub-id-type="doi">10.1016/j.immuni.2018.09.016</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sivick</surname><given-names>KE</given-names></name><etal/></person-group><article-title>Magnitude of Therapeutic STING Activation Determines CD8<sup>+</sup> T Cell-Mediated Anti-tumor Immunity</article-title><source>Cell Rep</source><year>2018</year><volume>25</volume><fpage>3074</fpage><lpage>3085</lpage><elocation-id>e5</elocation-id><pub-id pub-id-type="pmid">30540940</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gulen</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Signalling strength determines proapoptotic functions of STING</article-title><source>Nat Commun</source><year>2017</year><volume>8</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmcid">PMC5585373</pub-id><pub-id pub-id-type="pmid">28874664</pub-id><pub-id pub-id-type="doi">10.1038/s41467-017-00573-w</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><etal/></person-group><article-title>STING-mediated disruption of calcium homeostasis chronically activates ER stress and primes T cell death</article-title><source>Journal of Experimental Medicine</source><year>2019</year><volume>216</volume><fpage>867</fpage><lpage>883</lpage><pub-id pub-id-type="pmcid">PMC6446864</pub-id><pub-id pub-id-type="pmid">30886058</pub-id><pub-id pub-id-type="doi">10.1084/jem.20182192</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larkin</surname><given-names>B</given-names></name><etal/></person-group><article-title>Cutting Edge: Activation of STING in T Cells Induces Type I IFN Responses and Cell Death</article-title><source>The Journal of Immunology</source><year>2017</year><volume>199</volume><fpage>397</fpage><lpage>402</lpage><pub-id pub-id-type="pmcid">PMC5525333</pub-id><pub-id pub-id-type="pmid">28615418</pub-id><pub-id pub-id-type="doi">10.4049/jimmunol.1601999</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerboni</surname><given-names>S</given-names></name><etal/></person-group><article-title>Intrinsic antiproliferative activity of the innate sensor STING in T lymphocytes</article-title><source>Journal of Experimental Medicine</source><year>2017</year><volume>214</volume><fpage>1769</fpage><lpage>1785</lpage><pub-id pub-id-type="pmcid">PMC5461003</pub-id><pub-id pub-id-type="pmid">28484079</pub-id><pub-id pub-id-type="doi">10.1084/jem.20161674</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imanishi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Reciprocal regulation of STING and TCR signaling by mTORCI for T-cell activation and function</article-title><source>Life Sci Alliance</source><year>2019</year><volume>2</volume><pub-id pub-id-type="pmcid">PMC6348487</pub-id><pub-id pub-id-type="pmid">30683688</pub-id><pub-id pub-id-type="doi">10.26508/lsa.201800282</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Dobbs</surname><given-names>N</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Yan</surname><given-names>N</given-names></name></person-group><article-title>Interferon-Independent Activities of Mammalian STING Mediate Antiviral Response and Tumor Immune Evasion</article-title><source>Immunity</source><year>2020</year><volume>53</volume><fpage>115</fpage><lpage>126</lpage><elocation-id>e5</elocation-id><pub-id pub-id-type="pmcid">PMC7365768</pub-id><pub-id pub-id-type="pmid">32640258</pub-id><pub-id pub-id-type="doi">10.1016/j.immuni.2020.06.009</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhl</surname><given-names>N</given-names></name><etal/></person-group><article-title>STING agonism turns human T cells into interferon-producing cells but impedes their functionality</article-title><pub-id pub-id-type="pmcid">PMC9986811</pub-id><pub-id pub-id-type="pmid">36705069</pub-id><pub-id pub-id-type="doi">10.15252/embr.202255536</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><etal/></person-group><article-title>cGAS-STING–mediated DNA sensing maintains CD8<sup>+</sup> T cell stemness and promotes antitumor T cell therapy</article-title><source>Sci Transl Med</source><year>2020</year><volume>12</volume><fpage>9013</fpage><pub-id pub-id-type="pmid">32581136</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Naour</surname><given-names>J</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Trial watch: STING agonists in cancer therapy</article-title><source>Oncoimmunology</source><year>2020</year><volume>9</volume><pub-id pub-id-type="pmcid">PMC7466854</pub-id><pub-id pub-id-type="pmid">32934881</pub-id><pub-id pub-id-type="doi">10.1080/2162402X.2020.1777624</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maltbaek</surname><given-names>JH</given-names></name><name><surname>Cambier</surname><given-names>S</given-names></name><name><surname>Snyder</surname><given-names>JM</given-names></name><name><surname>Stetson</surname><given-names>DB</given-names></name></person-group><article-title>ABCC1 transporter exports the immunostimulatory cyclic dinucleotide cGAMP</article-title><source>Immunity</source><year>2022</year><volume>55</volume><fpage>1799</fpage><lpage>1812</lpage><elocation-id>e4</elocation-id><pub-id pub-id-type="pmcid">PMC9561016</pub-id><pub-id pub-id-type="pmid">36070769</pub-id><pub-id pub-id-type="doi">10.1016/j.immuni.2022.08.006</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><etal/></person-group><article-title>Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><pub-id pub-id-type="pmcid">PMC4709567</pub-id><pub-id pub-id-type="pmid">26754564</pub-id><pub-id pub-id-type="doi">10.1038/srep19049</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells</article-title><source>Immunity</source><year>2013</year><volume>38</volume><fpage>729</fpage><lpage>741</lpage><pub-id pub-id-type="pmid">23562161</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>L</given-names></name><etal/></person-group><article-title>STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors</article-title><source>Immunity</source><year>2014</year><volume>41</volume><fpage>843</fpage><lpage>852</lpage><pub-id pub-id-type="pmcid">PMC5155593</pub-id><pub-id pub-id-type="pmid">25517616</pub-id><pub-id pub-id-type="doi">10.1016/j.immuni.2014.10.019</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanpouille-Box</surname><given-names>C</given-names></name><etal/></person-group><article-title>DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity</article-title><source>Nat Commun</source><year>2017</year><volume>8</volume><elocation-id>15618</elocation-id><pub-id pub-id-type="pmcid">PMC5472757</pub-id><pub-id pub-id-type="pmid">28598415</pub-id><pub-id pub-id-type="doi">10.1038/ncomms15618</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glück</surname><given-names>S</given-names></name><etal/></person-group><article-title>Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence</article-title><source>Nat Cell Biol</source><year>2017</year><volume>19</volume><fpage>1061</fpage><lpage>1070</lpage><pub-id pub-id-type="pmcid">PMC5826565</pub-id><pub-id pub-id-type="pmid">28759028</pub-id><pub-id pub-id-type="doi">10.1038/ncb3586</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunphy</surname><given-names>G</given-names></name><etal/></person-group><article-title>Non-canonical Activation of the DNA Sensing Adaptor STING by ATM and IFI16 Mediates NF-κB Signaling after Nuclear DNA Damage</article-title><source>Mol Cell</source><year>2018</year><volume>71</volume><fpage>745</fpage><lpage>760</lpage><elocation-id>e5</elocation-id><pub-id pub-id-type="pmcid">PMC6127031</pub-id><pub-id pub-id-type="pmid">30193098</pub-id><pub-id pub-id-type="doi">10.1016/j.molcel.2018.07.034</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghaffari</surname><given-names>A</given-names></name><etal/></person-group><article-title>Sting agonist therapy in combination with pd-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in highgrade serous ovarian cancer</article-title><source>Br J Cancer</source><year>2018</year><volume>119</volume><fpage>440</fpage><lpage>449</lpage><pub-id pub-id-type="pmcid">PMC6133940</pub-id><pub-id pub-id-type="pmid">30046165</pub-id><pub-id pub-id-type="doi">10.1038/s41416-018-0188-5</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>L</given-names></name><etal/></person-group><article-title>PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer</article-title><source>Cell Rep</source><year>2018</year><volume>25</volume><fpage>2972</fpage><lpage>2980</lpage><elocation-id>e5</elocation-id><pub-id pub-id-type="pmcid">PMC6366450</pub-id><pub-id pub-id-type="pmid">30540933</pub-id><pub-id pub-id-type="doi">10.1016/j.celrep.2018.11.054</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>A</given-names></name><etal/></person-group><article-title>Radiotherapy promotes tumor-specific effector CD8<sup>+</sup> T cells via dendritic cell activation</article-title><source>J Immunol</source><year>2012</year><volume>189</volume><fpage>558</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">22685313</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surace</surname><given-names>L</given-names></name><name><surname>Scheifinger</surname><given-names>NA</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>van den Broek</surname><given-names>M</given-names></name></person-group><article-title>Radiotherapy supports tumor-specific immunity by acute inflammation</article-title><source>Oncoimmunology</source><year>2016</year><volume>5</volume><pub-id pub-id-type="pmcid">PMC4760297</pub-id><pub-id pub-id-type="pmid">26942071</pub-id><pub-id pub-id-type="doi">10.1080/2162402X.2015.1060391</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carozza</surname><given-names>JA</given-names></name><etal/></person-group><article-title>2’3’-cGAMP is an immunotransmitter produced by cancer cells and regulated by ENPP1</article-title><source>bioRxiv</source><year>2019</year><elocation-id>539312</elocation-id><pub-id pub-id-type="doi">10.1101/539312</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP</article-title><source>Immunity</source><year>2020</year><volume>52</volume><fpage>357</fpage><lpage>373</lpage><elocation-id>e9</elocation-id><pub-id pub-id-type="pmid">32049051</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lahey</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>LRRC8A:C/E Heteromeric Channels Are Ubiquitous Transporters of cGAMP</article-title><source>Mol Cell</source><year>2020</year><volume>80</volume><fpage>578</fpage><lpage>591</lpage><elocation-id>e5</elocation-id><pub-id pub-id-type="pmid">33171122</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>C</given-names></name><etal/></person-group><article-title>Transfer of cGAMP into Bystander Cells via LRRC8 Volume-Regulated Anion Channels Augments STING-Mediated Interferon Responses and Anti-viral Immunity</article-title><source>Immunity</source><year>2020</year><volume>52</volume><fpage>767</fpage><lpage>781</lpage><elocation-id>e6</elocation-id><pub-id pub-id-type="pmid">32277911</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Argüello</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>SCENITH: A flow cytometry based method to functionally profile energy metabolism with single cell resolution</article-title><source>Cell Metab</source><year>2020</year><volume>32</volume><fpage>1063</fpage><pub-id pub-id-type="pmcid">PMC8407169</pub-id><pub-id pub-id-type="pmid">33264598</pub-id><pub-id pub-id-type="doi">10.1016/j.cmet.2020.11.007</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>H</given-names></name><etal/></person-group><article-title>T cell-intrinsic STING signaling promotes regulatory T cell induction and immunosuppression by upregulating FOXP3 transcription in cervical cancer</article-title><source>J Immunother Cancer</source><year>2022</year><volume>10</volume><pub-id pub-id-type="pmcid">PMC9490630</pub-id><pub-id pub-id-type="pmid">36126994</pub-id><pub-id pub-id-type="doi">10.1136/jitc-2022-005151</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreatta</surname><given-names>M</given-names></name><name><surname>Carmona</surname><given-names>SJ</given-names></name></person-group><article-title>UCell: Robust and scalable single-cell gene signature scoring</article-title><source>Comput Struct Biotechnol J</source><year>2021</year><volume>19</volume><fpage>3796</fpage><lpage>3798</lpage><pub-id pub-id-type="pmcid">PMC8271111</pub-id><pub-id pub-id-type="pmid">34285779</pub-id><pub-id pub-id-type="doi">10.1016/j.csbj.2021.06.043</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabbagh</surname><given-names>L</given-names></name><etal/></person-group><article-title>The Selective Increase in Caspase-3 Expression in Effector but Not Memory T Cells Allows Susceptibility to Apoptosis</article-title><source>The Journal of Immunology</source><year>2004</year><volume>173</volume><fpage>5425</fpage><lpage>5433</lpage><pub-id pub-id-type="pmid">15494489</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouché</surname><given-names>N</given-names></name><name><surname>Scharlat</surname><given-names>A</given-names></name><name><surname>Snedden</surname><given-names>W</given-names></name><name><surname>Bouchez</surname><given-names>D</given-names></name><name><surname>Fromm</surname><given-names>H</given-names></name></person-group><article-title>A novel family of calmodulin-binding transcription activators in multicellular organisms</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>21851</fpage><lpage>21861</lpage><pub-id pub-id-type="pmid">11925432</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="web"><source>Grm7 glutamate receptor, metabotropic 7 [Mus musculus (house mouse)] - Gene - NCBI</source><comment><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/gene/108073">https://www.ncbi.nlm.nih.gov/gene/108073</ext-link></comment></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anastasiou</surname><given-names>M</given-names></name><etal/></person-group><article-title>Endothelial STING controls T cell transmigration in an IFNI-dependent manner</article-title><source>JCI Insight</source><year>2021</year><volume>6</volume><pub-id pub-id-type="pmcid">PMC8410041</pub-id><pub-id pub-id-type="pmid">34156982</pub-id><pub-id pub-id-type="doi">10.1172/jci.insight.149346</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demaria</surname><given-names>O</given-names></name><etal/></person-group><article-title>STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity</article-title><source>Proc Natl Acad Sci U S A</source><year>2015</year><volume>112</volume><fpage>15408</fpage><lpage>15413</lpage><pub-id pub-id-type="pmcid">PMC4687570</pub-id><pub-id pub-id-type="pmid">26607445</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1512832112</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>STING controls intestinal homeostasis through promoting antimicrobial peptide expression in epithelial cells</article-title><source>FASEB J</source><year>2020</year><volume>34</volume><elocation-id>15417</elocation-id><pub-id pub-id-type="pmcid">PMC7606834</pub-id><pub-id pub-id-type="pmid">32969062</pub-id><pub-id pub-id-type="doi">10.1096/fj.202001524R</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohkuri</surname><given-names>T</given-names></name><etal/></person-group><article-title>Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site</article-title><source>Cancer Immunology, Immunotherapy</source><year>2017</year><volume>66</volume><fpage>705</fpage><lpage>716</lpage><pub-id pub-id-type="pmcid">PMC11028681</pub-id><pub-id pub-id-type="pmid">28243692</pub-id><pub-id pub-id-type="doi">10.1007/s00262-017-1975-1</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>L</given-names></name><etal/></person-group><article-title>STING signaling promotes NK cell antitumor immunity and maintains a reservoir of TCF-1 + NK cells</article-title><source>Cell Rep</source><year>2023</year><volume>42</volume><elocation-id>113108</elocation-id><pub-id pub-id-type="pmid">37708030</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>MM</given-names></name><name><surname>Crute</surname><given-names>BW</given-names></name><name><surname>Cambier</surname><given-names>JC</given-names></name><name><surname>Getahun</surname><given-names>A</given-names></name></person-group><article-title>B cell intrinsic STING signaling triggers cell activation, synergizes with BCR signals and promotes antibody responses</article-title><source>J Immunol</source><year>2018</year><volume>201</volume><fpage>2641</fpage><pub-id pub-id-type="pmcid">PMC6497520</pub-id><pub-id pub-id-type="pmid">30282750</pub-id><pub-id pub-id-type="doi">10.4049/jimmunol.1701405</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Ren</surname><given-names>U</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Chena</surname><given-names>ZJ</given-names></name></person-group><article-title>CGAS is essential for cellular senescence</article-title><source>Proc Natl Acad Sci U S A</source><year>2017</year><volume>114</volume><fpage>E4612</fpage><lpage>E4620</lpage><pub-id pub-id-type="pmcid">PMC5468617</pub-id><pub-id pub-id-type="pmid">28533362</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1705499114</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corrales</surname><given-names>L</given-names></name><etal/></person-group><article-title>Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity</article-title><source>Cell Rep</source><year>2015</year><volume>11</volume><fpage>1018</fpage><lpage>1030</lpage><pub-id pub-id-type="pmcid">PMC4440852</pub-id><pub-id pub-id-type="pmid">25959818</pub-id><pub-id pub-id-type="doi">10.1016/j.celrep.2015.04.031</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ager</surname><given-names>CR</given-names></name><etal/></person-group><article-title>Intratumoral STING activation with T-cell checkpoint modulation generates systemic antitumor immunity</article-title><source>Cancer Immunol Res</source><year>2017</year><volume>5</volume><fpage>676</fpage><lpage>684</lpage><pub-id pub-id-type="pmcid">PMC5547907</pub-id><pub-id pub-id-type="pmid">28674082</pub-id><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-17-0049</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Guan</surname><given-names>W</given-names></name></person-group><article-title>STING Signaling Promotes Apoptosis, Necrosis, and Cell Death: An Overview and Update</article-title><source>Mediators Inflamm</source><year>2018</year><volume>2018</volume><pub-id pub-id-type="pmcid">PMC6286756</pub-id><pub-id pub-id-type="pmid">30595664</pub-id><pub-id pub-id-type="doi">10.1155/2018/1202797</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benoit-Lizon</surname><given-names>I</given-names></name><etal/></person-group><article-title>CD4 T cell-intrinsic STING signaling controls the differentiation and effector functions of TH1 and TH9 cells</article-title><source>J Immunother Cancer</source><year>2022</year><volume>10</volume><pub-id pub-id-type="pmcid">PMC8804688</pub-id><pub-id pub-id-type="pmid">35091453</pub-id><pub-id pub-id-type="doi">10.1136/jitc-2021-003459</pub-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prantner</surname><given-names>D</given-names></name><etal/></person-group><article-title>5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential</article-title><source>J Biol Chem</source><year>2012</year><volume>287</volume><fpage>39776</fpage><lpage>39788</lpage><pub-id pub-id-type="pmcid">PMC3501038</pub-id><pub-id pub-id-type="pmid">23027866</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M112.382986</pub-id></element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Downey</surname><given-names>CM</given-names></name><name><surname>Aghaei</surname><given-names>M</given-names></name><name><surname>Schwendener</surname><given-names>RA</given-names></name><name><surname>Jirik</surname><given-names>FR</given-names></name></person-group><article-title>DMXAA Causes Tumor Site-Specific Vascular Disruption in Murine Non-Small Cell Lung Cancer, and like the Endogenous Non-Canonical Cyclic Dinucleotide STING Agonist, 2’3’-cGAMP, Induces M2 Macrophage Repolarization</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><elocation-id>e99988</elocation-id><pub-id pub-id-type="pmcid">PMC4062468</pub-id><pub-id pub-id-type="pmid">24940883</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0099988</pub-id></element-citation></ref><ref id="R69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Concepcion</surname><given-names>AR</given-names></name><etal/></person-group><article-title>The volume-regulated anion channel LRRC8C suppresses T cell function by regulating cyclic dinucleotide transport and STING–p53 signaling</article-title><source>Nature Immunology 2022 23:2</source><year>2022</year><volume>23</volume><fpage>287</fpage><lpage>302</lpage><pub-id pub-id-type="pmcid">PMC8991407</pub-id><pub-id pub-id-type="pmid">35105987</pub-id><pub-id pub-id-type="doi">10.1038/s41590-021-01105-x</pub-id></element-citation></ref><ref id="R70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauer</surname><given-names>JD</given-names></name><etal/></person-group><article-title>The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides</article-title><source>Infect Immun</source><year>2011</year><volume>79</volume><fpage>688</fpage><lpage>694</lpage><pub-id pub-id-type="pmcid">PMC3028833</pub-id><pub-id pub-id-type="pmid">21098106</pub-id><pub-id pub-id-type="doi">10.1128/IAI.00999-10</pub-id></element-citation></ref><ref id="R71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>L</given-names></name><etal/></person-group><article-title>MPYS is required for IFN response factor 3 activation and type I IFN production in the response of cultured phagocytes to bacterial second messengers cyclic-di-AMP and cyclic-di-GMP</article-title><source>J Immunol</source><year>2011</year><volume>187</volume><fpage>2595</fpage><lpage>2601</lpage><pub-id pub-id-type="pmcid">PMC3159690</pub-id><pub-id pub-id-type="pmid">21813776</pub-id><pub-id pub-id-type="doi">10.4049/jimmunol.1100088</pub-id></element-citation></ref><ref id="R72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uccellini</surname><given-names>MB</given-names></name><name><surname>García-Sastre</surname><given-names>A</given-names></name></person-group><article-title>ISRE-Reporter Mouse Reveals High Basal and Induced Type I IFN Responses in Inflammatory Monocytes</article-title><source>Cell Rep</source><year>2018</year><volume>25</volume><fpage>2784</fpage><lpage>2796</lpage><elocation-id>e3</elocation-id><pub-id pub-id-type="pmcid">PMC6317368</pub-id><pub-id pub-id-type="pmid">30517866</pub-id><pub-id pub-id-type="doi">10.1016/j.celrep.2018.11.030</pub-id></element-citation></ref><ref id="R73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mombaerts</surname><given-names>P</given-names></name><etal/></person-group><article-title>Mutations in T-cell antigen receptor genes alpha and beta block thymocyte development at different stages</article-title><source>Nature</source><year>1992</year><volume>360</volume><fpage>225</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">1359428</pub-id></element-citation></ref><ref id="R74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>PP</given-names></name><etal/></person-group><article-title>A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival</article-title><source>Immunity</source><year>2001</year><volume>15</volume><fpage>763</fpage><lpage>774</lpage><pub-id pub-id-type="pmid">11728338</pub-id></element-citation></ref><ref id="R75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogquist</surname><given-names>KA</given-names></name><etal/></person-group><article-title>T cell receptor antagonist peptides induce positive selection</article-title><source>Cell</source><year>1994</year><volume>76</volume><fpage>17</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">8287475</pub-id></element-citation></ref><ref id="R76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Concordet</surname><given-names>JP</given-names></name><name><surname>Haeussler</surname><given-names>M</given-names></name></person-group><article-title>CRISPOR: intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens</article-title><source>Nucleic Acids Res</source><year>2018</year><volume>46</volume><fpage>W242</fpage><lpage>W245</lpage><pub-id pub-id-type="pmcid">PMC6030908</pub-id><pub-id pub-id-type="pmid">29762716</pub-id><pub-id pub-id-type="doi">10.1093/nar/gky354</pub-id></element-citation></ref><ref id="R77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becht</surname><given-names>E</given-names></name><etal/></person-group><article-title>Dimensionality reduction for visualizing single-cell data using UMAP</article-title><source>Nature Biotechnology 2018 37:1</source><year>2018</year><volume>37</volume><fpage>38</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">30531897</pub-id></element-citation></ref><ref id="R78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis</article-title><source>Cell</source><year>2015</year><volume>162</volume><fpage>184</fpage><lpage>197</lpage><pub-id pub-id-type="pmcid">PMC4508757</pub-id><pub-id pub-id-type="pmid">26095251</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2015.05.047</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>Induced expression of cancer-cell-intrinsic cGAS restricts tumor progression.</title><p><bold>A</bold> Experimental Setup. LLC or LLC<sup>cGAStetON</sup> cancer cells (2 x 10<sup>5</sup>) were s.c. injected into C57BL/6 mice. Cancer-cell-intrinsic cGAS expression was induced 14 days later by providing 5 mg/ml DOX in sucrose-sweetened (5% w/v) drinking water. Control mice did not receive DOX. Tumors were isolated 5 days after induced cGAS expression. <bold>B</bold> Western blot detecting cGAS on <italic>ex vivo</italic> tumor samples. <bold>C</bold> 2’3’-cGAMP quantification (ELISA). Two technical replicates each. The same amount of total protein was assayed. <bold>D</bold> Experimental setup. LLC or LLC<sup>cGAStetON</sup> cancer cells (2 x 10<sup>5</sup>) were s.c. injected into C57BL/6 mice. Cancer-cell-intrinsic cGAS expression was induced from the day of cancer cell injection as described in A. Control mice received no DOX. <bold>E</bold> Growth curve of LLC<sup>cGAStetON</sup> tumors (n = 6). The graphs show mean ± SD. Each symbol represents an individual mouse. Statistical analysis: Unpaired twotailed Student’s t-test per timepoint. <bold>F</bold> Growth curve of LLC tumors (n = 10). The graphs show mean ± SD. Each symbol represents an individual mouse. Statistical analysis: Unpaired two-tailed Student’s t-test per timepoint.</p></caption><graphic xlink:href="EMS199802-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>Cancer-cell-intrinsic cGAS promotes a sustained IFN-I response in the tumor microenvironment.</title><p><bold>A</bold> Experimental setup. LLC<sup>cGAStetON</sup> cells (2 x 10<sup>5</sup>) were s.c. injected into C57BL/6 or Mx1<sup>gfp</sup> IFN-I-response reporter mice. cGAS expression was induced by DOX during indicated periods. Control mice received no DOX. <bold>B</bold> Quantification of IFN-ß in tumor lysates after periods of induced cGAS expression (n = 3 per group). Each symbol represents an individual mouse. Statistical analysis: One-way ANOVA with Welch’s correction. <bold>C</bold> IFN-I response in intratumoral cell populations measured in Mx1<sup>gfp</sup> reporter mice 16 h after induction of cGAS expression (n = 6 per group). Each symbol represents an individual mouse. Statistical analysis: Two-way ANOVA. <bold>D</bold> Comparison of IFN-I-response in tumor derived DCs after induction of cGAS expression (n = 4-6 mice per group). Each symbol represents an individual mouse. Male and female mice were used. Statistical analysis: One-way ANOVA.</p></caption><graphic xlink:href="EMS199802-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>Induced expression of cancer-cell-intrinsic cGAS restricts tumor progression in a CD8<sup>+</sup> T cell-dependent fashion.</title><p><bold>A</bold> Experimental setup for B and C. LLC<sup>cGAStetON-OVA</sup> cells were s.c. injected into C57BL/6 mice. cGAS expression was induced by DOX from day 2 onwards until the endpoint. Control mice received no DOX. On day −1 and +5 relative to injection of cancer cells, mice received CD4- or CD8-depleting antibodies, or isotype as control. Each group consisted of 7-10 mice per group. <bold>B</bold> Tumor growth curves. Each symbol represents an individual mouse. Statistical analysis: Two-way ANOVA for data from day 21. <bold>C</bold> Survival curves. Death event is defined as tumor size ≥ 100 mm<sup>2</sup>.<bold>D</bold> Experimental setup for E-H. LLC<sup>cGAStetON-OVA</sup> cells were s.c. injected into C57BL/6 mice. Cancer-cell-intrinsic cGAS expression was induced by DOX from day 2 onwards until the endpoint. Control mice received no DOX. <bold>E</bold> Tumor weights at the endpoint (day 12). Each symbol represents an individual mouse. Statistical analysis: Two-tailed t-test with Welch’s correction. <bold>F</bold> UMAP dimensionality reduction representation overlaid with identified clusters per condition (+/– DOX). <bold>G</bold> Heatmap of relative marker expression per identified T cell cluster. Partial figure shown, refer to supplement for full figure. <bold>H</bold> Frequency of PD-1<sup>+</sup> and Ki-67<sup>+</sup> cells among CD8<sup>+</sup> T cells per condition. Each symbol represents an individual mouse. Statistical analysis: Twotailed t-test with Welch’s correction.</p></caption><graphic xlink:href="EMS199802-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>Concomitant TCR and STING signaling limits proliferation and metabolic activity of CD8<sup>+</sup> T cells <italic>in vitro</italic>.</title><p><bold>A</bold> Experimental setup. Either 5 x 10<sup>4</sup> CD45.1 <sup>+</sup> STING-proficient (STING<sup>+/+</sup>) or 5 x 10<sup>4</sup> CD45.1 +STING-deficient (STING<sup>−/−</sup>) OT-I CD8<sup>+</sup> T cells were stimulated with 10<sup>-6</sup> M SIINFEKL and 2 x 10<sup>5</sup> CD45.2+splenocytes as antigen-presenting cells in the presence or absence of 10 μg/mL added cGAMP. For D-F, OT-I T cells were labeled with CellTrace Violet before culture start. After 48 h (B, C, G) or 60 h (D-F), cells were collected and analyzed by flow cytometry after gating on single, live CD45.1<sup>+</sup> CD11b—CD8<sup>+</sup> cells. <bold>B</bold> Frequency of Ki-67<sup>+</sup> CD45.1<sup>+</sup> CD8<sup>+</sup> of total cells. <bold>C</bold> Frequency of GzmB<sup>+</sup> CD45.1<sup>+</sup> CD8<sup>+</sup> of total cells. <bold>D</bold> Representative proliferation curves of CellTrace violet-labelled OT-I cells. <bold>E</bold> Percentage of cells that underwent at least one proliferation cycle. <bold>F</bold> Frequency of live (LiveDead-NIR negative) CD8<sup>+</sup> T cells. Cells gated on single CD45.1+CD11b—CD8<sup>+</sup>. <bold>G</bold> Incorporated puromycin (PURO) as measure for metabolic activity in CD45.1<sup>+</sup> CD8<sup>+</sup> cells. Experimental groups in B, C and G were statistically compared using two-tailed t-test with Welch’s correction. Experimental groups in E and F were statistically compared using one-way ANOVA. Data from 3 biological replicates (spleens) are shown (B, C, E-G). ns, not significant.</p></caption><graphic xlink:href="EMS199802-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><title>STING-deficient CD8<sup>+</sup> T cells outcompete STING-proficient CD8<sup>+</sup> T cells in the tumor.</title><p><bold>A</bold> Experimental setup for B and C. LLC<sup>cGAStetON-OVA</sup> cells were s.c. injected into CD4<sup>Cre+/–</sup>STING<sup>flox</sup> or CD4<sup>Cre–/–</sup>STING<sup>flox</sup> littermates. cGAS expression was induced by DOX from day 2 onwards until the endpoint. <bold>B</bold> Tumor growth curves. Each symbol represents an individual mouse. Data from two pooled independent experiments with a total of 26-29 male and female mice. Statistical analysis: Two-way ANOVA. <bold>C</bold> Tumor weight at the endpoint. Statistical analysis: Two-tailed t-test. <bold>D</bold> Experimental setup for E-H. LLC<sup>OVA</sup> or LLC<sup>cGAStetON</sup>-<sup>OVA</sup> cells (3 x 105) were injected s.c. into male and female TCR&gt;<sup>−/−</sup> mice. cGAS expression was induced by DOX from day 2 onwards until the endpoint. On day 3, 1 x 10<sup>3</sup> CD45.1/45.1 STING<sup>–/–</sup> OT-I plus 1 x 10<sup>3</sup> CD45.1/45.2 STING<sup>+/+</sup> OT-I T cells were co-injected via the tail vein. The proportion OT-I cells was quantified in tumor and tumor-draining lymph nodes (dLNs) by flow cytometry at the endpoints. <bold>E</bold> Proportion of STING<sup>–/–</sup> and STING<sup>+/+</sup> OT-I cells at time of injection (day 0, left panel). Cells gated on single, live CD8<sup>+</sup> cells. Representative examples for the frequency of STING<sup>–/–</sup> and STING<sup>+/+</sup> OT-I cells in tumor (middle panel) and tdLN (right panel) 11 days after adoptive transfer. Cells were gated on single, live CD45<sup>+</sup>CD11b<sup>–</sup> TCRß<sup>+</sup> CD8<sup>+</sup> cells. <bold>F</bold> Proportion of STING<sup>– /–</sup> and STING<sup>+/+</sup> OT-I T cells at time of injection (day 0) and in LLC<sup>cGA</sup>S<sup>tetO</sup>N-<sup>OVA</sup> tumors 7 and 11 days after transfer. <bold>G</bold> Proportion of STING<sup>–/–</sup> and STING<sup>+/+</sup> OT-I T cells in tdLNs 11 days after transfer. <bold>H</bold> Proportion of STING<sup>–/–</sup> and STING<sup>+/+</sup> OT-I T cells in LLC<sup>OVA</sup> control tumors (no cGAS expression) 11 days after transfer. Experimental groups (F-H) were statistically compared using two-way ANOVA. Each symbol represents an individual mouse. Data from two pooled independent experiments with a total of 7-26 male and female mice. Data are expressed as mean ± SD.</p></caption><graphic xlink:href="EMS199802-f005"/></fig><fig id="F6" position="float"><label>Figure 6</label><caption><title>STING expression in CD8<sup>+</sup> T cells promotes their apoptosis and reduces their proliferation in a cGAMP-rich environment</title><p><bold>A</bold> Experimental setup. LLC<sup>cGAStetON</sup>-<sup>OVA</sup> cells (3 x 10<sup>5</sup>) were injected TCRß<sup>–/–</sup> mice. cGAS expression was induced by DOX from day 2 onwards until the endpoint. On day 3, 5 x 10<sup>3</sup> CD45.1/45.1 STING<sup>−/−</sup> OT-I plus 1 x 10<sup>3</sup> CD45.1/45.2 STING<sup>+/+</sup> OT-I T cells were co-injected via the tail vein. On day 9, CD8<sup>+</sup> T cells were sorted from tumors and subjected to single-cell whole transcriptome analysis. <bold>B</bold> UMAP representation of 12 (0-11) identified Seurat clusters. <bold>C</bold> Gene set enrichment analysis (GSEA) using Molecular Signatures Database (MSigDB) gene sets. <bold>D</bold> Global expression comparison of Casp3. <bold>E</bold> Ki67 expression in subsetted proliferating clusters 3 and 7, shown in the feature plot (left panel). Data are shown from 6 individually hashed mouse/tumor samples. Experimental groups were statistically compared using two-way ANOVA followed by Tukey’s Honest Significant Difference (HSD) test.</p></caption><graphic xlink:href="EMS199802-f006"/></fig></floats-group></article>